[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 148
1. Rodriguez FJ, Eberhart C, O'Neill BP, Slezak J, Burger PC, Goldthwaite P, Wu W, Giannini C: Histopathologic grading of adult medulloblastomas. Cancer; 2007 Jun 15;109(12):2557-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathologic grading of adult medulloblastomas.
  • BACKGROUND: Histopathologic evaluation of the degree and extent of anaplasia is a useful prognostic parameter in pediatric medulloblastomas.
  • Whether the same applies to adult medulloblastomas is not known.
  • METHODS: The study included 74 adult patients with histologically confirmed medulloblastomas and retrospectively reassessed 67 cases with available slides for the presence of nodularity, collagen deposition (desmoplasia without nodules), and degree and extent of anaplasia.
  • CONCLUSIONS: The incidence of severe anaplasia in adult medulloblastomas is lower than in the pediatric population.
  • [MeSH-major] Cerebellar Neoplasms / classification. Medulloblastoma / classification
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Female. Humans. Immunoenzyme Techniques. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Sex Distribution. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 American Cancer Society.
  • (PMID = 17487854.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


2. Koch A, Hrychyk A, Hartmann W, Waha A, Mikeska T, Waha A, Schüller U, Sörensen N, Berthold F, Goodyer CG, Wiestler OD, Birchmeier W, Behrens J, Pietsch T: Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas. Int J Cancer; 2007 Jul 15;121(2):284-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas.
  • Medulloblastomas (MBs) represent the most common malignant brain tumors in children.
  • These patients carry germline mutations in the APC tumor suppressor gene.
  • APC is part of a multiprotein complex involved in the Wnt signaling pathway that controls the stability of beta-catenin, the central effector in this cascade.
  • The pathway is negatively controlled by the tumor suppressor AXIN2 (Conductin), a scaffold protein of this signaling complex.
  • One MB displayed a somatic, tumor-specific 2 bp insertion in exon 5, leading to carboxy-terminal truncation of the AXIN2 protein.
  • This tumor biopsy showed nuclear accumulation of beta-catenin protein, indicating an activation of Wnt signaling.
  • [MeSH-major] Cytoskeletal Proteins / genetics. Medulloblastoma / pathology. Mutation. TCF Transcription Factors / metabolism. Transcription, Genetic
  • [MeSH-minor] Adolescent. Adult. Axin Protein. Base Sequence. Blotting, Western. Cell Line, Tumor. Cerebellum / embryology. Cerebellum / growth & development. Cerebellum / metabolism. Child. Child, Preschool. DNA Methylation. DNA Mutational Analysis. Female. Gene Expression Profiling. Humans. Infant. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction / genetics. Signal Transduction / physiology. Wnt1 Protein / genetics. Wnt1 Protein / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17373666.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AXIN2 protein, human; 0 / Axin Protein; 0 / Cytoskeletal Proteins; 0 / RNA, Messenger; 0 / TCF Transcription Factors; 0 / Wnt1 Protein
  •  go-up   go-down


3. Northcott PA, Fernandez-L A, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, Grundy R, Van Meter T, Rutka JT, Croce CM, Kenney AM, Taylor MD: The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res; 2009 Apr 15;69(8):3249-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors.
  • Medulloblastoma is the most common malignant pediatric brain tumor, and mechanisms underlying its development are poorly understood.
  • We identified recurrent amplification of the miR-17/92 polycistron proto-oncogene in 6% of pediatric medulloblastomas by high-resolution single-nucleotide polymorphism genotyping arrays and subsequent interphase fluorescence in situ hybridization on a human medulloblastoma tissue microarray.
  • Profiling the expression of 427 mature microRNAs (miRNA) in a series of 90 primary human medulloblastomas revealed that components of the miR-17/92 polycistron are the most highly up-regulated miRNAs in medulloblastoma.
  • Expression of miR-17/92 was highest in the subgroup of medulloblastomas associated with activation of the sonic hedgehog (Shh) signaling pathway compared with other subgroups of medulloblastoma.
  • Medulloblastomas in which miR-17/92 was up-regulated also had elevated levels of MYC/MYCN expression.
  • Consistent with its regulation by Shh, we observed that Shh treatment of primary cerebellar granule neuron precursors (CGNP), proposed cells of origin for the Shh-associated medulloblastomas, resulted in increased miR-17/92 expression.
  • We conclude that miR-17/92 is a positive effector of Shh-mediated proliferation and that aberrant expression/amplification of this miR confers a growth advantage to medulloblastomas.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2002 Jan 24;415(6870):436-42 [11807556.001]
  • [Cites] Cancer Cell. 2002 Jul;2(1):7-8 [12150819.001]
  • [Cites] Development. 2003 Jan;130(1):15-28 [12441288.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7331-6 [12777630.001]
  • [Cites] Development. 2004 Jan;131(1):217-28 [14660435.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] J Neurobiol. 2005 Sep 15;64(4):458-75 [16041741.001]
  • [Cites] Nucleic Acids Res. 2005;33(20):e179 [16314309.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1924-31 [16567768.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):699-704 [17943719.001]
  • [Cites] Nat Immunol. 2008 Apr;9(4):405-14 [18327259.001]
  • [Cites] Cell. 2008 Apr 18;133(2):217-22 [18423194.001]
  • [Cites] Blood. 2009 Jan 8;113(2):396-402 [18941111.001]
  • [Cites] Nat Genet. 2009 Apr;41(4):465-72 [19270706.001]
  • [Cites] PLoS One. 2008;3(8):e3088 [18769486.001]
  • (PMID = 19351822.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS061070-01; United States / NINDS NIH HHS / NS / R01 NS061070; United States / NINDS NIH HHS / NS / R01 NS061070-01; United States / NINDS NIH HHS / NS / R01NS061070
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hedgehog Proteins; 0 / MIRN17 microRNA, human; 0 / MicroRNAs; 0 / Proto-Oncogene Proteins c-myc; 0 / SHH protein, human
  • [Other-IDs] NLM/ NIHMS100132; NLM/ PMC2836891
  •  go-up   go-down


Advertisement
4. Hui AB, Takano H, Lo KW, Kuo WL, Lam CN, Tong CY, Chang Q, Gray JW, Ng HK: Identification of a novel homozygous deletion region at 6q23.1 in medulloblastomas using high-resolution array comparative genomic hybridization analysis. Clin Cancer Res; 2005 Jul 1;11(13):4707-16
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a novel homozygous deletion region at 6q23.1 in medulloblastomas using high-resolution array comparative genomic hybridization analysis.
  • PURPOSE: The aim of this study is to comprehensively characterize genome copy number aberrations in medulloblastomas using high-resolution array comparative genomic hybridization.
  • EXPERIMENTAL DESIGN: High-density genomic arrays containing 1,803 BAC clones were used to define recurrent chromosomal regions of gains or losses throughout the whole genome of medulloblastoma.
  • A series of 3 medulloblastoma cell lines and 16 primary tumors were investigated.
  • CONCLUSION: Current array comparative genomic hybridization analysis generates a comprehensive pattern of chromosomal aberrations in medulloblastomas.
  • This information will lead to a better understanding of medulloblastoma tumorigenesis.
  • The delineated regions of gains or losses will indicate locations of medulloblastoma-associated genes.
  • Frequent detection of reduced expression of AK091351 and KIAA1913 genes implicates them as suppressors of medulloblastoma tumorigenesis.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Chromosome Deletion. Chromosomes, Human, Pair 6 / genetics. Medulloblastoma / genetics. Nucleic Acid Hybridization / methods
  • [MeSH-minor] Adolescent. Adult. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Deletion. Gene Expression Regulation, Neoplastic. Genome, Human. Homozygote. Humans. In Situ Hybridization, Fluorescence. Male. Reverse Transcriptase Polymerase Chain Reaction. Tumor Suppressor Proteins / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16000565.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins
  •  go-up   go-down


5. Chargari C, Feuvret L, Levy A, Lamproglou I, Assouline A, Hemery C, Ghorbal L, Lopez S, Tep B, G GB, Lang P, Laigle-Donadey F, Cornu P, Mazeron JJ, Simon JM: Reappraisal of clinical outcome in adult medulloblastomas with emphasis on patterns of relapse. Br J Neurosurg; 2010 Aug;24(4):460-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reappraisal of clinical outcome in adult medulloblastomas with emphasis on patterns of relapse.
  • BACKGROUND: Clinical outcome and prognostic factors were assessed in adult medulloblastoma patients, with emphasis on patterns of relapse.
  • PATIENTS AND METHODS: Records of 36 consecutive adult patients with medulloblastoma were reviewed.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant / methods. Disease-Free Survival. Female. Humans. Magnetic Resonance Angiography. Male. Middle Aged. Outcome Assessment (Health Care). Prognosis. Radiotherapy, Adjuvant / methods. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726753.001).
  • [ISSN] 1360-046X
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Bai R, Siu IM, Tyler BM, Staedtke V, Gallia GL, Riggins GJ: Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas. Neuro Oncol; 2010 Jul;12(7):655-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas.
  • The homeobox transcription factor OTX2 plays an essential role during embryonic brain development.
  • It is normally silenced in the adult brain, but is overexpressed by genomic amplification or other mechanisms in the majority of medulloblastomas (MBs).
  • These findings suggest a mechanism for RA-mediated anti-tumor effect on OTX2-positive MB cells and indicate that therapeutic targeting of OTX2 might be effective if FGF pathway-mediated resistance can be overcome.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Oncol. 2005 Oct;27(4):1039-46 [16142321.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):919-24 [15705891.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Feb;65(2):176-86 [16462208.001]
  • [Cites] J Pediatr Psychol. 2007 Oct;32(9):1040-9 [17329318.001]
  • [Cites] Expert Opin Investig Drugs. 2008 Mar;17(3):437-43 [18321241.001]
  • [Cites] Med Pediatr Oncol. 2001 Jan;36(1):127-31 [11464864.001]
  • [Cites] Physiol Genomics. 1999 Aug 31;1(2):83-91 [11015565.001]
  • [Cites] Arch Dermatol Res. 2003 Nov;295(6):255-62 [14564458.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2002 Mar;282(3):E672-8 [11832372.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Development. 2002 Apr;129(7):1681-91 [11923204.001]
  • [Cites] Int J Biochem Cell Biol. 2002 Sep;34(9):1102-14 [12009305.001]
  • [Cites] Cancer Lett. 2003 Jul 18;197(1-2):185-92 [12880980.001]
  • [Cites] Nat Med. 2003 Aug;9(8):1033-8 [12872164.001]
  • [Cites] Neuron. 2003 Sep 25;40(1):65-79 [14527434.001]
  • [Cites] Nat Genet. 2009 Apr;41(4):465-72 [19270706.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3444-53 [15064731.001]
  • [Cites] EMBO J. 1993 Jul;12(7):2735-47 [8101484.001]
  • [Cites] J Neurosci. 1994 Oct;14(10):5725-40 [7931541.001]
  • [Cites] J Biol Chem. 1995 Jul 28;270(30):17850-7 [7629087.001]
  • [Cites] Brain Res. 1995 Dec 1;701(1-2):201-26 [8925285.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):790-5 [9053506.001]
  • [Cites] J Immunother Emphasis Tumor Immunol. 1996 Nov;19(6):405-13 [9041459.001]
  • [Cites] EMBO J. 1998 Oct 15;17(20):5896-904 [9774334.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):6951-61 [9819383.001]
  • [Cites] EMBO J. 1998 Dec 1;17(23):6790-8 [9843484.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):703-7 [15705863.001]
  • [Cites] Curr Pharm Des. 2006;12(3):379-85 [16454751.001]
  • (PMID = 20511190.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS052507
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Otx Transcription Factors; 0 / Otx2 protein, mouse; 5688UTC01R / Tretinoin
  • [Other-IDs] NLM/ PMC2940451
  •  go-up   go-down


7. McCabe MG, Ichimura K, Liu L, Plant K, Bäcklund LM, Pearson DM, Collins VP: High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol; 2006 Jun;65(6):549-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors.
  • Medulloblastomas and supratentorial primitive neuroectodermal tumors are aggressive childhood tumors.
  • We report our findings using array comparative genomic hybridization (CGH) on a whole-genome BAC/PAC/cosmid array with a median clone separation of 0.97 Mb to study 34 medulloblastomas and 7 supratentorial primitive neuroectodermal tumors.
  • In addition, one supratentorial primitive neuroectodermal tumor had lost both copies of the tumor-suppressor genes CDKN2A and CDKN2B.
  • Ten medulloblastomas had findings suggestive of isochromosome 17q.
  • In contrast to previous reports using conventional CGH, array CGH identified 3 distinct breakpoints in these cases: Ch 17: 17940393-19251679 (17p11.2, n = 6), Ch 17: 20111990-23308272 (17p11.2-17q11.2, n = 4), and Ch 17: 38425359-39091575 (17q21.31, n = 1).
  • Significant differences were found in the patterns of copy number change between medulloblastomas and supratentorial primitive neuroectodermal tumors, providing further evidence that these tumors are genetically distinct despite their morphologic and behavioral similarities.
  • [MeSH-major] Brain Neoplasms / genetics. Medulloblastoma / genetics. Neuroectodermal Tumors, Primitive / genetics. Nucleic Acid Hybridization / methods. Supratentorial Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Chromosome Aberrations. Gene Expression Profiling. Humans. In Situ Hybridization, Fluorescence / methods. Infant. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1990 Oct;8(2):279-85 [1979050.001]
  • [Cites] Oncogene. 2004 Mar 18;23(12):2250-63 [14968109.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1405-11 [14661059.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2 Suppl Pediatrics):187-93 [14758948.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7646-51 [14633684.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5271-81 [14614009.001]
  • [Cites] Nat Genet. 2003 Nov;35(3):197-8 [14593398.001]
  • [Cites] Int J Oncol. 2003 Oct;23(4):871-81 [12963965.001]
  • [Cites] Oncogene. 2003 Jun 19;22(25):3943-51 [12813468.001]
  • [Cites] Pediatr Neurosurg. 2000 Apr;32(4):187-91 [10940769.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Aug;121(1):67-72 [10958944.001]
  • [Cites] J Neurosurg. 2000 Sep;93(3):437-48 [10969942.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Oct 1;122(1):18-25 [11104027.001]
  • [Cites] Mol Pathol. 2000 Dec;53(6):313-9 [11193050.001]
  • [Cites] Clin Neurol Neurosurg. 2000 Dec;102(4):203-209 [11154805.001]
  • [Cites] J Neurosurg. 2001 Jul;95(1):9-14 [11453403.001]
  • [Cites] Nat Genet. 2001 Oct;29(2):143-52 [11544480.001]
  • [Cites] Brain Pathol. 2002 Jan;12(1):36-44 [11770900.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):842-9 [11821469.001]
  • [Cites] Int J Oncol. 2002 Mar;20(3):467-73 [11836556.001]
  • [Cites] Oncogene. 2002 Feb 21;21(9):1461-8 [11857089.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Feb;133(1):39-44 [11890988.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Mar-Apr;24(3):205-10 [11990307.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6205-10 [12414648.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Apr;36(4):361-74 [12619160.001]
  • [Cites] Pathology. 1999 Nov;31(4):337-44 [10643003.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):543-9 [10682663.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4707-16 [16000565.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jun;43(2):181-93 [15770670.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):49-57 [15545668.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):331-9 [10421270.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jul;25(3):230-40 [10379869.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1843-7 [10206302.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Dec;20(4):399-407 [9408757.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Aug;97(1):25-31 [9242214.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):1065-72 [8806696.001]
  • (PMID = 16783165.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6618
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2816352; NLM/ UKMS2695
  •  go-up   go-down


8. Schüller U, Koch A, Hartmann W, Garrè ML, Goodyer CG, Cama A, Sörensen N, Wiestler OD, Pietsch T: Subtype-specific expression and genetic alterations of the chemokinereceptor gene CXCR4 in medulloblastomas. Int J Cancer; 2005 Oct 20;117(1):82-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtype-specific expression and genetic alterations of the chemokinereceptor gene CXCR4 in medulloblastomas.
  • As medulloblastomas (MBs), the most common malignant brain tumors of childhood, are believed to arise from neuronal cerebellar precursors, we asked whether there is a potential role for Cxcr4 in the pathogenesis of MB.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Medulloblastoma / genetics. Receptors, CXCR4 / genetics
  • [MeSH-minor] Adolescent. Adult. Amino Acid Substitution. Basic Helix-Loop-Helix Transcription Factors. Child. Child, Preschool. DNA / genetics. DNA Mutational Analysis. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Gene Expression Regulation, Neoplastic. Humans. Infant. Middle Aged. Mutation / genetics. Nerve Tissue Proteins / genetics. Nerve Tissue Proteins / metabolism. Oncogene Proteins / genetics. Oncogene Proteins / metabolism. Polymorphism, Single-Stranded Conformational. RNA / genetics. RNA, Messenger / analysis. Receptor, Nerve Growth Factor. Receptors, Nerve Growth Factor / genetics. Receptors, Nerve Growth Factor / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Trans-Activators. Transcription Factors / genetics. Transcription Factors / metabolism. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15880586.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ATOH1 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / Gli protein; 0 / Nerve Tissue Proteins; 0 / Oncogene Proteins; 0 / RNA, Messenger; 0 / Receptor, Nerve Growth Factor; 0 / Receptors, CXCR4; 0 / Receptors, Nerve Growth Factor; 0 / Trans-Activators; 0 / Transcription Factors; 63231-63-0 / RNA; 9007-49-2 / DNA
  •  go-up   go-down


9. Brandes AA, Franceschi E: Neuro-oncology: Genetic variation in pediatric and adult brain tumors. Nat Rev Neurol; 2010 Dec;6(12):653-4
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuro-oncology: Genetic variation in pediatric and adult brain tumors.
  • Two new studies suggest that pediatric medulloblastomas and high-grade gliomas are genetically different from the same tumors in adults.
  • Age-dependent gene expression might affect tumor biology; therefore, therapies for adult medulloblastomas or gliomas might not produce the same clinical outcomes in pediatric patients, and vice versa.
  • [MeSH-major] Brain Neoplasms / genetics. Cerebellar Neoplasms / genetics. Gene Expression Profiling. Glioma / genetics. Medulloblastoma / genetics
  • [MeSH-minor] Adult. Child. Genetic Variation. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21131914.001).
  • [ISSN] 1759-4766
  • [Journal-full-title] Nature reviews. Neurology
  • [ISO-abbreviation] Nat Rev Neurol
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  •  go-up   go-down


10. Dagostino C, Clara E, Chio A, Giordana MT: Morphophenotype of medulloblastoma in children and adults. The size of nuclei. Clin Neuropathol; 2006 Sep-Oct;25(5):227-31
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphophenotype of medulloblastoma in children and adults. The size of nuclei.
  • OBJECTIVE: Uniform cells with round, regular nuclei characterize the typical histologic aspect of medulloblastoma.
  • Enlargement of nuclei distinguishes the large-cell medulloblastoma variant and is associated with a poor prognosis in pediatric medulloblastomas.
  • The aim of the present study was to compare the size of nuclei between pediatric and adult medulloblastomas by a morphometric analysis.
  • MATERIAL AND METHODS: In 79 neurosurgical specimens of cerebellar medulloblastomas, the maximum nuclear diameter of the largest nuclei was measured.
  • Measurements were performed with a digital-image analysis system.
  • RESULTS: The difference between the mean values in children and adults was statistically significant (p = 0,001).
  • The distribution of maximum values measured in each case had two distinct peaks in the two age groups, in 3.5% of adult cases and in more than 30% of pediatric cases the maximum nuclear size was superior to 12 microm.
  • CONCLUSIONS: The present results show that nuclei of tumor cells in pediatric medulloblastomas are larger than those in adult medulloblastomas and confirm that the phenotype of medulloblastoma is different in the two age groups.
  • Distinct genetic events can, thus, underlie medulloblastoma in childhood and adult age, the prognostic role of genetic variables can differ by age.
  • [MeSH-major] Cell Nucleus / ultrastructure. Cerebellar Neoplasms / ultrastructure. Medulloblastoma / ultrastructure
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Female. Humans. Image Processing, Computer-Assisted. Infant. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17007445.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


11. Franceschi E, Tosoni A, Paioli A, Cavallo G, Spagnolli F, Brandes AA: Challenges and progress in the treatment of adult medulloblastomas. Future Oncol; 2007 Apr;3(2):115-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges and progress in the treatment of adult medulloblastomas.
  • [MeSH-major] Cerebellar Neoplasms / therapy. Medulloblastoma / therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant / trends. Humans. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17381408.001).
  • [ISSN] 1479-6694
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  •  go-up   go-down


12. Holland H, Koschny R, Krupp W, Meixensberger J, Bauer M, Schober R, Kirsten H, Ganten TM, Ahnert P: Cytogenetic and molecular biological characterization of an adult medulloblastoma. Cancer Genet Cytogenet; 2007 Oct 15;178(2):104-13
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic and molecular biological characterization of an adult medulloblastoma.
  • Medulloblastoma is a malignant invasive embryonal tumor, occurring in children mainly.
  • It is rare in adults (<1% of adult brain tumors), and so comprehensive cytogenetic and molecular biological data on adult medulloblastomas are very limited.
  • We performed comprehensive cytogenetic analyses of an adult medulloblastoma, WHO grade IV, using trypsin-Giemsa staining (GTG-banding), multicolor fluorescence in situ hybridization (M-FISH), and locus-specific FISH, complemented by molecular karyotyping using high-density single nucleotide polymorphism (SNP) arrays.
  • Molecular karyotyping by SNP array confirmed chromosomal changes -2p, -10q, -16q, and -Xq and revealed de novo partial uniparental disomy 1q and 9q.
  • Applying an upcoming therapeutic approach, we found that primary medulloblastoma cells were resistant to TRAIL, a novel anticancer cytokine, but could be efficiently sensitized by cotreatment with the proteasome inhibitor bortezomib.
  • Bortezomib-TRAIL cotreatment may serve as a powerful therapeutic option for medulloblastoma patients.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Medulloblastoma / genetics
  • [MeSH-minor] Adult. Child. Chromosome Aberrations. Chromosome Banding. Female. Flow Cytometry. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Matrix Metalloproteinase 2 / genetics. Phosphopyruvate Hydratase / genetics. Polymorphism, Single Nucleotide. Synaptophysin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954265.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Synaptophysin; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


13. Ongürü O, Karslioglu Y, Ozcan A, Celik E: Anti-apoptotic and growth-promoting markers in adult medulloblastomas. Clin Neuropathol; 2010 Nov-Dec;29(6):384-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-apoptotic and growth-promoting markers in adult medulloblastomas.
  • AIM: the aim of this study was to investigate the pathologic features, proliferation potential and expression of some anti-apoptotic and growth-promoting markers in adult medulloblastomas.
  • METHOD: we analyzed the immunohistochemical expression of survivin, c-KIT, Bcl-2, fascin, p-53 and Ki-67 in 18 adult medulloblastomas (> 16 years of age).
  • 14 cases were classical, 2 desmoplastic/nodular and 2 large cell medulloblastomas.
  • Moderate-to-high nuclear survivin expression was observed with high percentages (55 - 100%) in all medulloblastomas while Bcl-2 was mildly positive in only 1 case.
  • Fascin expression was observed in 13 medulloblastomas (72%), 9 of which showing moderate to high immunoreactivity.
  • CONCLUSION: frequent nuclear survivin expression implies the predominance of anti-apoptotic factors in pathogenesis of adult medulloblastomas.
  • It may also be a potential therapeutic target for adult medulloblastomas.
  • Although Blc-2 immunoreactivity was previously reported in approximately 30% in medulloblastomas, we have observed that it is rarely expressed in the present series of adult medulloblastomas.
  • To our knowledge, this is the first study evaluating fascin expression in medulloblastomas.
  • Mild-to-moderate cytoplasmic c-KIT immunoreactivity without membranous staining in adult medulloblastomas may support the previous studies reporting low level of c-KIT protein expression with lack of activating mutations in medulloblastomas.
  • It seems p53 is rarely involved in the course of develepment of adult medulloblastomas.
  • [MeSH-major] Apoptosis Regulatory Proteins / metabolism. Cerebellar Neoplasms / metabolism. Growth Substances / metabolism. Medulloblastoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / metabolism. Carrier Proteins / metabolism. Female. Humans. Inhibitor of Apoptosis Proteins. Male. Microfilament Proteins / metabolism. Microtubule-Associated Proteins / metabolism. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-kit / metabolism. Retrospective Studies. Tumor Suppressor Protein p53 / metabolism. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21073843.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Growth Substances; 0 / Inhibitor of Apoptosis Proteins; 0 / Microfilament Proteins; 0 / Microtubule-Associated Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 146808-54-0 / fascin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


14. Giordana MT, D'Agostino C, Pollo B, Silvani A, Ferracini R, Paiolo A, Ghiglione P, Chiò A: Anaplasia is rare and does not influence prognosis in adult medulloblastoma. J Neuropathol Exp Neurol; 2005 Oct;64(10):869-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplasia is rare and does not influence prognosis in adult medulloblastoma.
  • Histopathologic grading based on increasing anaplasia predicts clinical behavior of pediatric medulloblastomas.
  • The present study was aimed at grading 86 medulloblastomas of adult patients (aged 18 and older) by anaplasia and analyzing the predictive power.
  • Severe nuclear pleomorphism was found in 4 of 86 cases; the only large-cell medulloblastoma was from an 18-year-old patient.
  • The histologic spectrum of medulloblastoma in adults is different from that in children.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / pathology
  • [MeSH-minor] Adult. Aged. Anaplasia. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16215458.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


15. Smee RI, Williams JR: Medulloblastomas-primitive neuroectodermal tumours in the adult population. J Med Imaging Radiat Oncol; 2008 Feb;52(1):72-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastomas-primitive neuroectodermal tumours in the adult population.
  • Medulloblastomas - primitive neuroectodermal tumours are rare in adults.
  • The medulloblastoma - primitive neuroectodermal tumour database was evaluated for all patients aged more than 18 years who were referred for management.
  • There were two posterior fossa recurrences, with associated supratentorial and extra central nervous system disease.
  • The outcome for adults matches that of the more common paediatric patients.
  • [MeSH-major] Cerebellar Neoplasms / epidemiology. Medulloblastoma / epidemiology. Neuroectodermal Tumors, Primitive / epidemiology
  • [MeSH-minor] Adolescent. Adult. Databases, Factual / statistics & numerical data. Female. Follow-Up Studies. Humans. Intracranial Pressure. Male. Neoplasm Recurrence, Local. Neurosurgical Procedures. New South Wales / epidemiology. Radiotherapy, Adjuvant. Rare Diseases. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18373831.001).
  • [ISSN] 1754-9477
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 29
  •  go-up   go-down


16. Yamashita Y, Kumabe T, Higano S, Watanabe M, Tominaga T: Minimum apparent diffusion coefficient is significantly correlated with cellularity in medulloblastomas. Neurol Res; 2009 Nov;31(9):940-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimum apparent diffusion coefficient is significantly correlated with cellularity in medulloblastomas.
  • The purpose of this study was to evaluate the relationship between ADC and tumor cellularity in medulloblastoma and other posterior fossa tumors.
  • METHODS: Pre-operative diffusion-weighted MR images were retrospectively reviewed in 26 patients with posterior fossa neoplasms: 11 medulloblastomas, one atypical teratoid/rhabdoid tumor (AT/RT), four glioblastomas, four ependymomas, three pilocytic astrocytomas and three hemangioblastomas.
  • The minimum ADC (minADC) value of each tumor was determined on ADC maps derived from isotropic diffusion-weighted MR images.
  • Tumor cellularity measured in surgical specimens was compared with the minADC value by simple linear regression analysis.
  • RESULTS: The mean minADC value of the medulloblastoma was significantly lower than those of ependymoma, pilocytic astrocytoma and hemangioblastoma without overlap in the range of minADC values.
  • Therefore, medulloblastomas could be clearly differentiated by absolute minADC values.
  • AT/RT and glioblastoma had similar minADC values to medulloblastoma.
  • Tumor cellularity was negatively correlated with the minADC value in medulloblastomas and other posterior fossa tumors.
  • DISCUSSION: The low minADC value of medulloblastomas reflects the high tumor cellularity.
  • Analysis of ADC values has high predictive value for the differentiation of medulloblastoma from other posterior fossa tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Diffusion Magnetic Resonance Imaging / methods. Medulloblastoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / metabolism. Astrocytoma / pathology. Astrocytoma / physiopathology. Body Water / physiology. Cell Count. Child. Child, Preschool. Diagnosis, Differential. Diffusion. Ependymoma / metabolism. Ependymoma / pathology. Ependymoma / physiopathology. Extracellular Space / metabolism. Female. Hemangioblastoma / metabolism. Hemangioblastoma / pathology. Hemangioblastoma / physiopathology. Humans. Infant. Male. Middle Aged. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19138469.001).
  • [ISSN] 1743-1328
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Pfister SM, Remke M, Benner A, Werft W, Mendrzyk F, Scheurlen W, Kulozik A, Lichter P, Korshunov A: Use of CDK6 oncogene amplification and 17q gain to predict poor clinical risk groups in adult medulloblastoma. J Clin Oncol; 2009 May 20;27(15_suppl):2030

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of CDK6 oncogene amplification and 17q gain to predict poor clinical risk groups in adult medulloblastoma.
  • : 2030 Background: While in children medulloblastoma comprises the most common malignant brain tumor, it accounts for only 1% of intracranial malignancies in adults.
  • The infrequent appearance of MB in adults poses the question, whether these tumors are the same in adults and children in terms of biological and clinical peculiarities.
  • METHODS: Array-CGH was performed for a total 34 adult medulloblastoma samples (>18 years) and results were compared with data from 101 pediatric patients.
  • Selected genomic regions were further investigated by FISH analysis in an independent cohort of 415 samples (112 adult and 303 pediatric).
  • All 146 adult patients received a standard treatment regimen consisting of tumor resection, irradiation of the neuroaxis with 36 Gy, a boost of 20-23 Gy to the posterior fossa, and eight cycles of vincristin, lomustine, and cisplatin.
  • RESULTS: Copy-number gains of chromosome 17q as well as high-level amplifications of CDK6 were identified as significant adverse prognostic markers in adult medulloblastoma.
  • Apart from one exception, CDK6 amplifications were only observed in adult patients (9% in adults versus 0.2 % in children), whereas amplifications of MYC or MYCN were significantly overrepresented in the pediatric cohort, but when present were also associated with dismal prognosis in adults.
  • Based on these results, we propose a molecular staging system for adult medulloblastoma: i) cases with oncogene amplification (10% of cases, 5-year OS = 0%);.
  • CONCLUSIONS: We report on the largest cohort of adult medulloblastoma investigated for genomic imbalances to date.
  • We propose a model for the molecular risk stratification of adult medulloblastoma comprising three distinct genomic risk groups with significantly different survival and tumor biology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964634.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. de Haas T, Oussoren E, Grajkowska W, Perek-Polnik M, Popovic M, Zadravec-Zaletel L, Perera M, Corte G, Wirths O, van Sluis P, Pietsch T, Troost D, Baas F, Versteeg R, Kool M: OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. J Neuropathol Exp Neurol; 2006 Feb;65(2):176-86

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas.
  • We previously described a high OTX2 expression in medulloblastoma.
  • Here, we analyzed amplification and mRNA expression of OTX1 and OTX2 in a series of human medulloblastomas.
  • The OTX2 gene was amplified in the medulloblastoma cell line D425 and mRNA and protein data showed expression in 114 of 152 medulloblastomas (75%), but not in postnatal cerebellum.
  • Northern blot (n = 10) and reverse transcriptase-polymerase chain reaction (n = 45) analyses demonstrated that virtually all medulloblastomas expressed OTX1, OTX2, or both.
  • OTX2 mRNA expression correlated with a classic medulloblastoma histology (29 of 34 cases), whereas expression of OTX1 mRNA only was correlated with a nodular/desmoplastic histology (9 of 11 cases).
  • Immunohistochemical analysis of a series of classic medulloblastomas detected OTX2 protein expression in 83 of 107 (78%) cases.
  • In addition, OTX2-positive tumors were mainly found in children, but OTX2-negative tumors occurred in 2 patient groups: very young patients (<5 years) and adults (>20 years).
  • Nodular/desmoplastic medulloblastomas are thought to arise from the external granular layer (EGL).
  • However, it is unclear whether classic medulloblastomas also originate from the EGL or from the ventricular matrix.
  • Analysis of human fetal brain showed OTX2 protein expression in a small number of presumptive neuronal precursor cells of the EGL, but not in precursor cells of the ventricular matrix.
  • Combined with data from rodents, our results therefore suggest that both nodular/desmoplastic and at least part of the classic medulloblastomas originate from cells of the EGL, albeit from different regions.
  • [MeSH-major] Medulloblastoma. Otx Transcription Factors / metabolism
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cerebellum / growth & development. Cerebellum / metabolism. Cerebellum / pathology. Child. Child, Preschool. Female. Fetus / anatomy & histology. Fetus / physiology. Humans. Infant. Infant, Newborn. Male. Middle Aged. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462208.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / OTX1 protein, human; 0 / OTX2 protein, human; 0 / Otx Transcription Factors; 0 / RNA, Messenger
  •  go-up   go-down


19. Lo KC, Rossi MR, Eberhart CG, Cowell JK: Genome wide copy number abnormalities in pediatric medulloblastomas as assessed by array comparative genome hybridization. Brain Pathol; 2007 Jul;17(3):282-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome wide copy number abnormalities in pediatric medulloblastomas as assessed by array comparative genome hybridization.
  • Array-based comparative genomic hybridization was used to characterize 22 medulloblastomas in order to precisely define genetic alterations in these malignant childhood brain tumors.
  • Amplifications in this series included MYCL, MYCN and MYC previously implicated in medulloblastoma pathogenesis, as well as novel amplicons on chromosomes 2, 4, 11 and 12.
  • As a result of this combined analysis of 72 samples, we have defined specific regions on chromosomes 1, 8p, 10q, 11p and 16q which are frequently involved in CNAs in medulloblastomas.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Chromosome Aberrations. Chromosomes, Human / genetics. Gene Dosage / genetics. Medulloblastoma / genetics. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Chromosome Mapping. Female. Follow-Up Studies. Gene Expression Profiling / methods. Humans. In Situ Hybridization. Male. Pediatrics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465989.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 104504; United States / NCI NIH HHS / CA / CA 16056
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


20. Abe M, Tokumaru S, Tabuchi K, Kida Y, Takagi M, Imamura J: Stereotactic radiation therapy with chemotherapy in the management of recurrent medulloblastomas. Pediatr Neurosurg; 2006;42(2):81-8
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiation therapy with chemotherapy in the management of recurrent medulloblastomas.
  • Medulloblastomas are highly lethal tumors when they recur.
  • This report documents the preliminary study results of a treatment for recurrent medulloblastomas consisting of stereotactic radiation therapy (SRT) with chemotherapy.
  • The reduction in tumor size after SRT was often remarkable.
  • In contrast, all 8 patients with metastasis had new lesions either in the spinal canal or on the surface of the brain outside the target area of SRT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / therapy. Medulloblastoma / therapy. Neoplasm Recurrence, Local / therapy. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Peripheral Blood Stem Cell Transplantation. Radiotherapy Dosage. Retrospective Studies

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 16465076.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


21. Misaki K, Marukawa K, Hayashi Y, Fukusato T, Minamoto T, Hasegawa M, Yamashita J, Fujisawa H: Correlation of gamma-catenin expression with good prognosis in medulloblastomas. J Neurosurg; 2005 Mar;102(2 Suppl):197-206
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of gamma-catenin expression with good prognosis in medulloblastomas.
  • OBJECT: Medulloblastoma is a malignant cerebellar tumor of childhood and is difficult to cure due to frequent cerebrospinal fluid dissemination.
  • METHODS: Immunohistochemical and cytogenetic examinations of beta- and gamma-catenin, c-myc, N-myc, and cyclin D1 in 24 primary medulloblastomas were conducted, and their clinical relevance was evaluated.
  • By differential polymerase chain reaction, c-myc and N-myc were amplified separately in two large cell/anaplastic medulloblastomas.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Cytoskeletal Proteins / genetics. Genes, myc / genetics. Medulloblastoma / genetics
  • [MeSH-minor] Adolescent. Adult. Antibodies, Neoplasm / immunology. Blotting, Western. Child. Child, Preschool. Combined Modality Therapy. DNA Mutational Analysis. DNA Primers / genetics. Desmoplakins. Genes, bcl-1 / immunology. Humans. Immunohistochemistry. Infant. Point Mutation / genetics. Polymerase Chain Reaction. Prognosis. RNA, Messenger / genetics. Trans-Activators / genetics. Trans-Activators / immunology. beta Catenin. gamma Catenin

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16156230.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / DNA Primers; 0 / Desmoplakins; 0 / JUP protein, human; 0 / RNA, Messenger; 0 / Trans-Activators; 0 / beta Catenin; 0 / gamma Catenin
  •  go-up   go-down


22. Kaszper E, Hanzély Z, Szende B, Dabasi G, Garami M, Schuler D, Hauser P: [Examination of somatostatin receptor expression in recurrent childhood medulloblastomas]. Magy Onkol; 2008 Dec;52(4):351-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Examination of somatostatin receptor expression in recurrent childhood medulloblastomas].
  • Medulloblastoma is the most common malignant pediatric central nervous system tumor.
  • Despite the adequate therapy the tumor often recurs.
  • The primary medulloblastoma expresses somatostatin receptor-2 (SSTR-2), but so far we had no experience about the receptor status in recurrent tumors.
  • The presence of SSTR-2 may have an important role in the early detection and treatment of recurrent medulloblastomas.
  • Our aim was to examine the state of SSTR-2 expression in recurrent childhood medulloblastomas.
  • We examined SSTR-2 expression by immunohistochemistry in primary and recurrent medulloblastoma samples of ten children treated with recurrent medulloblastoma at Semmelweis University, Departments of Pediatrics, between 1998 and 2004.
  • We examined the intensity and the percentage of SSTR-2-positive tumor cells in the primary and recurrent tumor samples.
  • All primary tumors were receptor-positive and SSTR-2 was also expressed in all recurrent medulloblastomas.
  • In our samples the percentage of SSTR-2-positive tumor cells was 30-90%.
  • As a conclusion, SSTR-2-positive recurrent tumors can be detected early by Octreoscan imaging, and the presence of SSTR-2 establishes the opportunity of applying somatostatin analogues (octreotide) in the treatment of recurrent childhood medulloblastoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cerebellar Neoplasms / chemistry. Medulloblastoma / chemistry. Neoplasm Recurrence, Local / chemistry. Receptors, Somatostatin / analysis
  • [MeSH-minor] Adolescent. Antineoplastic Agents, Hormonal / therapeutic use. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Indium Radioisotopes. Infant. Male. Octreotide / therapeutic use. Predictive Value of Tests. Somatostatin / analogs & derivatives. Tomography, Emission-Computed, Single-Photon / methods. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068462.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Indium Radioisotopes; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 51110-01-1 / Somatostatin; G083B71P98 / pentetreotide; RWM8CCW8GP / Octreotide
  •  go-up   go-down


23. Muñoz-Mármol AM, Mola G, Ruiz-Larroya T, Fernández-Vasalo A, Vela E, Mate JL, Ariza A: Rarity of JC virus DNA sequences and early proteins in human gliomas and medulloblastomas: the controversial role of JC virus in human neurooncogenesis. Neuropathol Appl Neurobiol; 2006 Apr;32(2):131-40
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rarity of JC virus DNA sequences and early proteins in human gliomas and medulloblastomas: the controversial role of JC virus in human neurooncogenesis.
  • Moreover, JCV genomic DNA and early viral protein T-antigen have been detected in various types of human central nervous system (CNS) neoplasms.
  • To further explore this association we have studied paraffin-embedded brain biopsy tissue from 60 neoplasms (55 gliomas and five medulloblastomas) and 15 reactive gliosis cases for the presence of JCV DNA sequences and proteins.
  • Additionally, IHC with both antibodies was applied to a tissue micro-array including 109 CNS tumours and 21 reactive gliosis samples.
  • The rarity of JCV DNA sequences and early proteins in our brain tumours enriches the controversy over the role of JCV in human neurooncogenesis, whose clarification is in need of further molecular and epidemiologic studies.
  • [MeSH-major] Brain Neoplasms / virology. DNA, Viral / isolation & purification. Glioma / virology. JC Virus / genetics. Medulloblastoma / virology
  • [MeSH-minor] Adult. Animals. Antigens, Viral, Tumor / isolation & purification. Cell Transformation, Neoplastic. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16599942.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / DNA, Viral
  •  go-up   go-down


24. Korshunov A, Remke M, Werft W, Benner A, Ryzhova M, Witt H, Sturm D, Wittmann A, Schöttler A, Felsberg J, Reifenberger G, Rutkowski S, Scheurlen W, Kulozik AE, von Deimling A, Lichter P, Pfister SM: Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol; 2010 Jun 20;28(18):3054-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
  • PURPOSE: Medulloblastoma (MB) is the most common malignant brain tumor in children, whereas it rarely presents in adults.
  • We aimed to identify genetic aberrations in 146 adult MBs to evaluate age-dependent differences in tumor biology and adapt age-specific risk stratification models.
  • METHODS: As a screening set, we studied a cohort of 34 adult MBs by using array-based comparative genomic hybridization comparing molecular results with clinical data.
  • DNA copy number aberrations identified as possible prognostic markers were validated in an independent cohort of 112 adult patients with MB by fluorescent in situ hybridization analysis.
  • RESULTS: CDK6 amplification, 10q loss, and 17q gain are the most powerful prognostic markers in adult MB.
  • Whereas MYC/MYCN oncogene amplifications had a high prognostic value in pediatric MB, these aberrations were rarely observed in adult tumors.
  • Surprisingly, adult MBs with 6q deletion and nuclear beta-catenin activation did not share the excellent prognosis with their pediatric counterparts.
  • CONCLUSION: Adult MB is distinct from pediatric MB in terms of genomic aberrations and their impact on clinical outcomes.
  • Therefore, adult MBs require age-specific risk stratification models.
  • We propose a molecular staging system involving three distinct risk groups based on DNA copy number status of 10q and 17q.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Chromosome Aberrations. Medulloblastoma / genetics. Nuclear Proteins / genetics. Oncogene Proteins / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adolescent. Adult. Algorithms. Biomarkers, Tumor / genetics. Carcinoma, Large Cell / classification. Carcinoma, Large Cell / genetics. Carcinoma, Large Cell / metabolism. Child. Child, Preschool. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 6 / genetics. Comparative Genomic Hybridization. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Infant. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis. Risk Assessment. Tissue Array Analysis. Young Adult. beta Catenin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479417.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MYC protein, human; 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / Proto-Oncogene Proteins c-myc; 0 / beta Catenin
  •  go-up   go-down


25. Terterov S, Krieger MD, Bowen I, McComb JG: Evaluation of intracranial cerebrospinal fluid cytology in staging pediatric medulloblastomas, supratentorial primitive neuroectodermal tumors, and ependymomas. J Neurosurg Pediatr; 2010 Aug;6(2):131-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of intracranial cerebrospinal fluid cytology in staging pediatric medulloblastomas, supratentorial primitive neuroectodermal tumors, and ependymomas.
  • OBJECT: The objective of this study was to determine the role of intracranial CSF examination in detecting true cases of early tumor dissemination.
  • Cerebrospinal fluid dissemination is an ominous feature of pediatric brain tumors, occurring in as many as 30% of medulloblastomas, 25% of supratentorial primitive neuroectodermal tumors (PNETs), and 5% of ependymomas at diagnosis.
  • METHODS: Under an institutional review board-approved protocol, medical records, pathology reports, and radiology reports for 150 patients who had undergone resection of brain tumors (88 with medulloblastomas, 21 with supratentorial PNETs, and 41 with ependymomas) and who had been evaluated using neuraxis MR imaging studies in the last 15 years were retrospectively reviewed.
  • CONCLUSIONS: Discordance exists between the results of neuraxis MR imaging and lumbar and intracranial CSF cytology in perioperative detection of tumor dissemination for pediatric medulloblastoma, supratentorial PNETs, and ependymoma.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebrospinal Fluid / cytology. Ependymoma / pathology. Medulloblastoma / pathology. Neuroectodermal Tumors, Primitive / pathology. Supratentorial Neoplasms / pathology
  • [MeSH-minor] Adolescent. Brain / pathology. Brain / surgery. Cerebellum / pathology. Cerebellum / surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Neoplasm Staging. Predictive Value of Tests. Radiotherapy, Adjuvant. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20672933.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Germanwala AV, Mai JC, Tomycz ND, Niranjan A, Flickinger JC, Kondziolka D, Lunsford LD: Boost Gamma Knife surgery during multimodality management of adult medulloblastoma. J Neurosurg; 2008 Feb;108(2):204-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Boost Gamma Knife surgery during multimodality management of adult medulloblastoma.
  • OBJECT: The aim of this paper was to determine prognostic factors for adult medulloblastoma treated with boost Gamma Knife surgery (GKS) following resection and craniospinal irradiation.
  • METHODS: The authors performed a retrospective analysis of 12 adult patients with histologically proven medulloblastoma or supratentorial primitive neuroectodermal tumor who between February 1991 and December 2004 underwent >or=1 sessions of GKS for posttreatment residual or recurrent tumors (6 tumors in each group).
  • Stereotactic radiosurgery was applied to residual and recurrent posterior fossa tumor as well as to foci of intracranial medulloblastoma metastases.
  • The mean GKS-treated tumor volume was 9.4 cm3 (range 0.5-39 cm3).
  • RESULTS: Following adjunctive radiosurgery, 5 patients had no evidence of tumor on magnetic resonance (MR) imaging, 3 patients had stable tumor burden on MR imaging, and 4 patients had evidence of tumor progression locally with or without intracranial metastases.
  • All patients with tumor progression died.
  • The majority of patients who achieved tumor eradication (80%) and tumor stabilization (67%) after GKS had residual tumor as the reason for their referral for GKS.
  • The best outcomes were attained in patients with residual disease who were younger, had smaller tumor volumes, had no evidence of metastatic disease, and had received higher cumulative GKS doses.
  • CONCLUSIONS: Single or multiple GKS sessions were a well-tolerated, feasible, and effective adjunctive treatment for posterior fossa residual or recurrent medulloblastoma as well as intracranial metastatic medulloblastoma in adult patients.
  • [MeSH-major] Cerebellar Neoplasms / surgery. Medulloblastoma / surgery. Neoadjuvant Therapy. Radiosurgery / methods
  • [MeSH-minor] Adult. Age Factors. Chemotherapy, Adjuvant. Cranial Irradiation. Disease Progression. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual. Neuroectodermal Tumors / radiotherapy. Neuroectodermal Tumors / surgery. Remission Induction. Retrospective Studies. Spine / radiation effects. Supratentorial Neoplasms / radiotherapy. Supratentorial Neoplasms / surgery. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240913.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Phi JH, Kim JH, Eun KM, Wang KC, Park KH, Choi SA, Kim YY, Park SH, Cho BK, Kim SK: Upregulation of SOX2, NOTCH1, and ID1 in supratentorial primitive neuroectodermal tumors: a distinct differentiation pattern from that of medulloblastomas. J Neurosurg Pediatr; 2010 Jun;5(6):608-14
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upregulation of SOX2, NOTCH1, and ID1 in supratentorial primitive neuroectodermal tumors: a distinct differentiation pattern from that of medulloblastomas.
  • OBJECT: Supratentorial primitive neuroectodermal tumor (PNET) and medulloblastoma are highly malignant embryonal brain tumors.
  • The authors compared the expression of specific genes involved in neuroglial differentiation in supratentorial PNETs and medulloblastomas to define the distinct characters of these tumors.
  • METHODS: The mRNA expression of 8 genes (SOX2, NOTCH1, ID1, ASCL-1, NEUROD1, NEUROG1, NEUROG2, and NRG1) was evaluated in 25 embryonal tumors (12 supratentorial PNETs and 13 medulloblastomas) by quantitative real-time polymerase chain reaction.
  • The expression levels of the transcripts of these genes were compared between the tumor groups.
  • RESULTS: Supratentorial PNETs expressed significantly higher levels of SOX2, NOTCH1, ID1, and ASCL-1 transcripts, whereas the transcription of proneural basic helix-loop-helix factors, NEUROD1, NEUROG1 (significantly), and NEUROG2 (not significantly) was upregulated in medulloblastomas.
  • The proportion of phosphorylated STAT3alpha relative to STAT3alpha was significantly greater in supratentorial PNETs than in medulloblastomas, indicating activation of the JAK/STAT3 pathway in supratentorial PNETs.
  • CONCLUSIONS: These results indicate that supratentorial PNET predominantly has glial features and medulloblastoma largely follows a neuronal differentiation pattern.
  • These divergent differentiation patterns may be related to the location and origin of each tumor.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Inhibitor of Differentiation Protein 1 / genetics. Medulloblastoma / genetics. Neuroectodermal Tumors, Primitive / genetics. Receptor, Notch1 / genetics. SOXB1 Transcription Factors / genetics. STAT3 Transcription Factor / genetics. Supratentorial Neoplasms / genetics. Up-Regulation / genetics
  • [MeSH-minor] Adolescent. Adult. Cerebellum / pathology. Cerebral Cortex / pathology. Child. Child, Preschool. Diagnosis, Differential. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Infant. Infant, Newborn. Male. Neuroglia / pathology. Neurons / pathology. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515335.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ID1 protein, human; 0 / Inhibitor of Differentiation Protein 1; 0 / NOTCH1 protein, human; 0 / RNA, Messenger; 0 / Receptor, Notch1; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human
  •  go-up   go-down


28. Korshunov AG, Sycheva RV, Gorelyshev SK, Ozerov SS, Golanov AV: [Chromosome 17 abnormalities in medulloblastomas and their prognostic value]. Zh Vopr Neirokhir Im N N Burdenko; 2008 Apr-Jun;(2):3-5; discussion 5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chromosome 17 abnormalities in medulloblastomas and their prognostic value].
  • The interphasic cytogenetic analysis of chromosome 17 abnormalities in medulloblastoma biopsy specimens may be recommended for its inclusion into a complex of laboratory diagnostic methods used in the examination of these tumors.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 17 / genetics. Medulloblastoma / genetics
  • [MeSH-minor] Adolescent. Adult. Female. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Predictive Value of Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18724421.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


29. Li XN, Shu Q, Su JM, Adesina AM, Wong KK, Perlaky L, Antalffy BA, Blaney SM, Lau CC: Differential expression of survivin splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol; 2007 Feb;33(1):67-76
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of survivin splice isoforms in medulloblastomas.
  • The current study was undertaken to examine the mRNA expression of survivin isoforms and their correlation with clinical staging and outcome in 20 medulloblastoma (MB) tumours, three MB cell lines and normal brain tissues (a foetal and an adult cerebellum) by densitometry scanning of 32p-dCTP incorporated reverse transcription polymerase chain reaction (RT-PCR) products and quantitative real-time PCR.
  • Our results showed that the normal adult brain only expressed low levels of survivin-deltaEx3 mRNA, while the foetal brain expressed all three isoforms, with wild-type survivin as the dominant transcript.
  • [MeSH-major] Cerebellar Neoplasms / metabolism. Medulloblastoma / metabolism. Microtubule-Associated Proteins / biosynthesis. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Glyceraldehyde-3-Phosphate Dehydrogenases / metabolism. Humans. Immunohistochemistry. Infant. Inhibitor of Apoptosis Proteins. Isomerism. Male. Neoplasm Staging. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239009.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


30. Barnes M, Eberhart CG, Collins R, Tihan T: Expression of p75NTR in fetal brain and medulloblastomas: evidence of a precursor cell marker and its persistence in neoplasia. J Neurooncol; 2009 Apr;92(2):193-201

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p75NTR in fetal brain and medulloblastomas: evidence of a precursor cell marker and its persistence in neoplasia.
  • p75 neurotrophin receptor (p75NTR) is a member of the tumor necrosis factor superfamily, and plays a significant role in nervous system development. p75NTR has a dual (proliferative/apoptotic) role in neurogenesis and binds pro-neurotrophins with high affinity.
  • Recent work suggests p75NTR is overexpressed in the developing cerebellum and in nodular/desmoplastic medulloblastomas.
  • We analyzed p75NTR expression in various parts of the fetal and adult human central nervous system, and in 75 patients with medulloblastomas.
  • The expression of p75NTR in the fetal brain was seen solely within the external granular layer with weaker expression in the Purkinje layer, which most likely represents Purkinje cell staining.
  • The staining was present in gestational weeks 20-40, while no staining was identified elsewhere in the fetal brain or within the adult cerebellum. p75NTR positive cells were also positive with the proliferation marker ki-67, but were negative for ret, reelin, CD133, CD34, and cleaved caspase 3.
  • Nine of 75 medulloblastomas (12%) were also showed positive immunostaining for p75NTR.
  • The staining was seen in four classic, two desmoplastic, and three anaplastic medulloblastomas.
  • The persistence of p75NTR in a small group of medulloblastomas raises the possibility that in such tumors, the receptor could be a potential therapeutic target.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain / metabolism. Cerebellar Neoplasms / metabolism. Medulloblastoma / metabolism. Receptor, Nerve Growth Factor / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19066726.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptor, Nerve Growth Factor
  •  go-up   go-down


31. Riffaud L, Saikali S, Leray E, Hamlat A, Haegelen C, Vauleon E, Lesimple T: Survival and prognostic factors in a series of adults with medulloblastomas. J Neurosurg; 2009 Sep;111(3):478-87
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and prognostic factors in a series of adults with medulloblastomas.
  • OBJECT: In this article, the authors report their experience in the management of adult patients with medulloblastoma at their institution to identify prognostic factors important for survival and disease control.
  • METHODS: Between 1977 and 2005, 27 patients who were >or=16 years old and had medulloblastoma were treated consecutively.
  • Six patients had the desmoplastic variant, and 21 patients presented with classic medulloblastoma.
  • Patient age, duration of symptoms, Karnofsky Performance Scale score at presentation, hydrocephalus, tumor location, brainstem invasion, extent of resection, histological subtype, preradiotherapy chemotherapy, risk group, and period of presentation were not significant variables.
  • Eleven patients suffered tumor recurrence within a median time of 4.2 years.
  • All patients in whom the tumor recurred have died despite aggressive treatments.
  • CONCLUSIONS: Long-term survival is possible in adults treated for medulloblastoma.
  • Tumor recurrences should be treated with aggressive therapies as some patients may have sustained response.
  • [MeSH-major] Cerebellar Neoplasms / mortality. Medulloblastoma / mortality
  • [MeSH-minor] Adolescent. Adult. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prognosis. Quality of Life. Sex Factors. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19231932.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Ang C, Hauerstock D, Guiot MC, Kasymjanova G, Roberge D, Kavan P, Muanza T: Characteristics and outcomes of medulloblastoma in adults. Pediatr Blood Cancer; 2008 Nov;51(5):603-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcomes of medulloblastoma in adults.
  • BACKGROUND: Adult medulloblastoma is a rare disease for which there is no internationally accepted standard of care.
  • We sought to review the presentation, management, and outcome of patients with adult medulloblastoma treated at the McGill University teaching hospitals over the past 18 years.
  • METHODS: Medical records were reviewed to gather demographic and clinical data including presenting symptoms, tumor characteristics, management, survival, and treatment toxicity.
  • CONCLUSION: Adult medulloblastoma has distinct characteristics from the pediatric population including presentation in the lateral cerebellar hemispheres.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / therapy. Medulloblastoma / pathology. Medulloblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Chemotherapy, Adjuvant / adverse effects. Combined Modality Therapy. Cranial Irradiation. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Neurosurgical Procedures. Radiotherapy, Adjuvant / adverse effects. Salvage Therapy / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18649371.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Szathmari A, Thiesse P, Galand-desmé S, Mottolese C, Bret P, Jouanneau E, Guyotat J, Lion-François L, Frappaz D: Correlation between pre- or postoperative MRI findings and cerebellar sequelae in patients with medulloblastomas. Pediatr Blood Cancer; 2010 Dec 15;55(7):1310-6
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between pre- or postoperative MRI findings and cerebellar sequelae in patients with medulloblastomas.
  • INTRODUCTION: Immediate and delayed cerebellar dysfunction may be expected after surgical resection of a medulloblastoma.
  • MATERIAL AND METHODS: The data of 31 patients in continuous complete remission after removal of medulloblastoma, irradiation and chemotherapy, were retrospectively reviewed.
  • Magnetic Resonance Imaging (MRI) was analyzed for the following items: preoperative MRI (ratio of the surface of the tumor/posterior fossa, presence of ventricular dilatation or tonsilar hernia, involvement of the dentate nucleus) and delayed post-operative MRI (amount of cerebellar parenchyma removed, degree of cerebellar atrophy, presence of T1 hypointense regions in remaining cerebellar area and removal of region containing dentate nucleus).
  • RESULTS: On preoperative MRI, the ratio of the surface of the tumor/posterior fossa and the presence of tonsilar hernia were significantly correlated with long-term sequelae on speech (respectively P = 0.027 and P = 0.05).
  • [MeSH-major] Cerebellar Neoplasms / surgery. Magnetic Resonance Imaging. Medulloblastoma / surgery. Postoperative Complications
  • [MeSH-minor] Adolescent. Adult. Atrophy. Cerebellum / pathology. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Intracranial Hypertension / etiology. Intracranial Hypertension / pathology. Male. Young Adult

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20981689.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Kagawa N, Maruno M, Suzuki T, Hashiba T, Hashimoto N, Izumoto S, Yoshimine T: Detection of genetic and chromosomal aberrations in medulloblastomas and primitive neuroectodermal tumors with DNA microarrays. Brain Tumor Pathol; 2006 Apr;23(1):41-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of genetic and chromosomal aberrations in medulloblastomas and primitive neuroectodermal tumors with DNA microarrays.
  • Medulloblastoma (MB) is the most frequent infratentorial malignant brain tumor in children.
  • In contrast, primitive neuroectodermal tumor (PNET) is defined as a supratentorial malignant tumor generated from the cerebral hemisphere.
  • We investigated the amplification and/or deletion of genes and the chromosomal gain and/or loss in 10 MBs and 3 PNETs with a genomic DNA microarray system.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Cerebellar Neoplasms / pathology. Chromosome Aberrations. DNA, Neoplasm / genetics. Medulloblastoma / genetics. Medulloblastoma / pathology. Neuroectodermal Tumors, Primitive / genetics. Neuroectodermal Tumors, Primitive / pathology
  • [MeSH-minor] Biomarkers, Tumor. Cerebellum / pathology. Child. Child, Preschool. Female. Humans. In Situ Hybridization. Infant. Male. Microarray Analysis. Young Adult


35. Padovani L, André N, Carrie C, Muracciole X: [Childhood and adult medulloblastoma: what difference?]. Cancer Radiother; 2009 Oct;13(6-7):530-5
Genetic Alliance. consumer health - Medulloblastoma, childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Childhood and adult medulloblastoma: what difference?].
  • [Transliterated title] Le médulloblastome de l'enfant et de l'adulte: quelle différence?
  • Medulloblastoma is the most frequent childhood brain tumor (30%) but account only for less than 1% of adult brain tumor.
  • Due to the rarety in adult population, no prospective studies and few data about late effects are available.
  • Adult medulloblastoma is a therapeutic challenge and their therapeutic strategies are similar to pediatric protocols.
  • In order to improve the understanding of adult disease and to homogenize the treatment, National Cancer Institute (INCa) stimulated the creation of web conference to discuss each case prospectively and to propose a protocol of treatment.
  • A better comprehension of biological processes and abnormal cellular signalling pathways involved in medulloblastoma pathogenesis had led toward a new prognostic classification to adapt the therapeutic strategy and gives hope of new therapeutic tools.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Medulloblastoma / pathology
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Brain Neoplasms / epidemiology. Child. Cognition Disorders / epidemiology. Cognition Disorders / etiology. Combined Modality Therapy. France / epidemiology. Humans. Incidence. Molecular Biology / methods. Radiotherapy / adverse effects. Radiotherapy / methods. Surgical Procedures, Operative

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19713143.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


36. Secondino S, Citterio A, Pedrazzoli P, Funaioli C, Scialfa GG, Siena S: Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy. Anticancer Res; 2008 Nov-Dec;28(6B):3991-2
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy.
  • We report on radiological abnormalities resembling recurrent tumor in adult medulloblastoma receiving intensified chemotherapy and radiotherapy.
  • Evidence provided in this paper confirms previous reports in the pediatric population and suggests that neuroradiologist and medical oncologists should be aware of new possible radiological findings related to aggressive treatments for brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Medulloblastoma / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19192661.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


37. Selek U, Zorlu F, Hurmuz P, Cengiz M, Turker A, Soylemezoglu F, Gurkaynak M: Craniospinal radiotherapy in adult medulloblastoma. Strahlenther Onkol; 2007 May;183(5):236-40
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniospinal radiotherapy in adult medulloblastoma.
  • PURPOSE: To evaluate the outcome and prognostic factors of adult patients with medulloblastoma.
  • PATIENTS AND METHODS: 26 adult medulloblastoma patients with a median age of 27 were subjected to craniospinal radiotherapy.
  • Patient characteristics, treatment factors and tumor characteristics failed to show any significance in univariate analysis.
  • [MeSH-major] Cerebellar Neoplasms / radiotherapy. Cranial Irradiation. Medulloblastoma / radiotherapy. Spine / radiation effects
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Prognosis. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497094.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


38. Nordfors K, Haapasalo J, Korja M, Niemelä A, Laine J, Parkkila AK, Pastorekova S, Pastorek J, Waheed A, Sly WS, Parkkila S, Haapasalo H: The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis. BMC Cancer; 2010;10:148
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis.
  • BACKGROUND: Medulloblastomas (MBs) and supratentorial primitive neuroectodermal tumours (PNETs) are the most common highly aggressive paediatric brain tumours.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carbonic Anhydrase II / analysis. Carbonic Anhydrases / analysis. Cerebellar Neoplasms / enzymology. Medulloblastoma / enzymology. Neuroectodermal Tumors, Primitive / enzymology. Supratentorial Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis. Chi-Square Distribution. Child. Child, Preschool. Cytoplasm / enzymology. Endothelial Cells / enzymology. Female. Finland. Humans. Immunohistochemistry. Infant. Infant, Newborn. Kaplan-Meier Estimate. Male. Middle Aged. Odds Ratio. Proportional Hazards Models. Time Factors. Treatment Outcome. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Hum Reprod. 2000 Jan;6(1):68-74 [10611263.001]
  • [Cites] BMC Cancer. 2008;8:1 [18173856.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2220-4 [10688890.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Dec;26(6):504-12 [11123716.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7075-83 [11156414.001]
  • [Cites] Bioorg Med Chem. 2001 Mar;9(3):703-14 [11310605.001]
  • [Cites] Expert Opin Investig Drugs. 2003 Feb;12(2):283-7 [12556221.001]
  • [Cites] Int J Cancer. 2003 Jul 20;105(6):873-81 [12767076.001]
  • [Cites] Exp Cell Res. 2003 Nov 1;290(2):332-45 [14567991.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):666-75 [15497120.001]
  • [Cites] J Enzyme Inhib Med Chem. 2004 Jun;19(3):199-229 [15499993.001]
  • [Cites] J Histochem Cytochem. 1983 Jul;31(7):879-86 [6406590.001]
  • [Cites] Cancer Metastasis Rev. 1987;5(4):343-65 [2882864.001]
  • [Cites] Virology. 1992 Apr;187(2):620-6 [1312272.001]
  • [Cites] Histochemistry. 1993 Jan;99(1):37-41 [8468192.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):690-8 [7931615.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] Acta Neuropathol. 1994;88(6):520-6 [7879598.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Annu Rev Biochem. 1995;64:375-401 [7574487.001]
  • [Cites] Br J Cancer. 1996 Mar;73(5):620-3 [8605096.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):896-9 [9500446.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7608-13 [9636197.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596-601 [9770531.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Nov-Dec;20(6):520-7 [9856671.001]
  • [Cites] J Urol. 2004 Dec;172(6 Pt 1):2158-61 [15538222.001]
  • [Cites] World J Gastroenterol. 2005 Jan 14;11(2):155-63 [15633208.001]
  • [Cites] J Neurobiol. 2005 Sep 15;64(4):458-75 [16041741.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):465-75 [16212811.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7621-31 [16234523.001]
  • [Cites] Biochem J. 2005 Nov 15;392(Pt 1):83-92 [16083424.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8201-7 [16299253.001]
  • [Cites] Cancer Biol Ther. 2005 Oct;4(10):1055-62 [16294030.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] Neuro Oncol. 2008 Apr;10(2):131-8 [18322268.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):395-400 [18464292.001]
  • [Cites] J Biol Chem. 2008 Oct 10;283(41):27799-809 [18703501.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1319-23 [18485615.001]
  • [Cites] Cancer Res. 2009 Jan 1;69(1):358-68 [19118021.001]
  • [Cites] Br J Neurosurg. 2009 Aug;23(4):364-75 [19637007.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16233-8 [19805286.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):246-54 [16618579.001]
  • [Cites] Neurol India. 2006 Mar;54(1):16-23 [16679637.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5190-200 [16707443.001]
  • [Cites] Acta Neuropathol. 2006 Jul;112(1):5-12 [16685513.001]
  • [Cites] BMC Dev Biol. 2006;6:22 [16719910.001]
  • [Cites] Int J Oncol. 2006 Oct;29(4):1025-33 [16964400.001]
  • [Cites] Adv Clin Chem. 2006;42:167-216 [17131627.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4109-17 [16931630.001]
  • [Cites] Histopathology. 2006 Dec;49(6):594-602 [17163844.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):308-13 [17435181.001]
  • [Cites] Cancer Biol Ther. 2007 Jan;6(1):70-5 [17172824.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Cancer Immun. 2007;7:14 [17705350.001]
  • [Cites] Nat Rev Drug Discov. 2008 Feb;7(2):168-81 [18167490.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):577-84 [10666387.001]
  • (PMID = 20398423.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; EC 4.2.1.- / Carbonic Anhydrase II; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases; EC 4.2.1.1 / carbonic anhydrase XII
  • [Other-IDs] NLM/ PMC2874782
  •  go-up   go-down


39. Das P, Puri T, Suri V, Sharma MC, Sharma BS, Sarkar C: Medulloblastomas: a correlative study of MIB-1 proliferation index along with expression of c-Myc, ERBB2, and anti-apoptotic proteins along with histological typing and clinical outcome. Childs Nerv Syst; 2009 Jul;25(7):825-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastomas: a correlative study of MIB-1 proliferation index along with expression of c-Myc, ERBB2, and anti-apoptotic proteins along with histological typing and clinical outcome.
  • BACKGROUND: Medulloblastoma (MB) is the most common pediatric brain tumor.
  • It is however rare in adults.
  • The genetic and protein expression profile of medulloblastoma is complex, which is worthwhile in terms of prognostication and development or selection of targeted therapy.
  • AIMS AND OBJECTIVES: The aims and objectives to correlate the MIB-1 proliferation index and protein expression profiles of c-Myc, ERBB2, and anti-apoptotic proteins (Bcl2 and Bcl-xL) in tumor cells with histological subtypes and clinical outcome.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / physiopathology. Cell Proliferation. Medulloblastoma / diagnosis. Medulloblastoma / physiopathology
  • [MeSH-minor] Adolescent. Adult. Brain / pathology. Brain / physiopathology. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Prognosis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-myc / metabolism. Receptor, ErbB-2 / metabolism. Young Adult. bcl-X Protein / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444455.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / Ki-67 Antigen; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-myc; 0 / bcl-X Protein; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


40. Howes TL, Buatti JM, Kirby PA, Carlisle TL, Ryken TC: Radiation induced adult medulloblastoma: a case report. J Neurooncol; 2006 Nov;80(2):191-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation induced adult medulloblastoma: a case report.
  • Adult medulloblastoma is a rare intracranial tumor.
  • Our patient is a 61 year old woman treated with cranial irradiation 15 years previously for a low grade astrocytoma in the left posterior temporal lobe that was recently diagnosed with medulloblastoma in the right cerebellum.
  • This is the first reported case of radiation induced adult medulloblastoma.
  • [MeSH-major] Cerebellar Neoplasms / etiology. Medulloblastoma / etiology. Neoplasms, Radiation-Induced / pathology
  • [MeSH-minor] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Craniotomy. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neurosurgical Procedures. Temporal Lobe / pathology

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710747.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


41. Gessi M, Monego G, Calviello G, Lanza P, Giangaspero F, Silvestrini A, Lauriola L, Ranelletti FO: Human parathyroid hormone-related protein and human parathyroid hormone receptor type 1 are expressed in human medulloblastomas and regulate cell proliferation and apoptosis in medulloblastoma-derived cell lines. Acta Neuropathol; 2007 Aug;114(2):135-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human parathyroid hormone-related protein and human parathyroid hormone receptor type 1 are expressed in human medulloblastomas and regulate cell proliferation and apoptosis in medulloblastoma-derived cell lines.
  • Human parathyroid hormone-related protein (hPTHrP), identified in patients with paraneoplastic hypercalcemia and expressed by different cell types during development and adult life, plays important roles in many human neoplasms.
  • Immunohistochemical and RT-PCR analyses of hPTHrP and human parathyroid hormone receptor type 1 (PTHR-1) in primary medulloblastoma confirmed their expression in both classic and desmoplastic variants at RNA and protein levels.
  • To evaluate the functional role of hPTHrP, DAOY and D283 medulloblastoma and U87MG glioma cells, expressing high levels of hPTHrP and PTHR-1, were treated with anti-sense oligonucleotides for hPTHrP.
  • This study indicates that hPTHrP and PTHR-1 are expressed in medulloblastoma and could promote tumor growth, protecting cells from apoptosis.
  • [MeSH-major] Apoptosis / physiology. Cell Proliferation. Medulloblastoma / metabolism. Parathyroid Hormone-Related Protein / biosynthesis. Receptor, Parathyroid Hormone, Type 1 / biosynthesis
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. Gene Expression. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Oligonucleotides, Antisense. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Medulloblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17372745.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / Parathyroid Hormone-Related Protein; 0 / Receptor, Parathyroid Hormone, Type 1
  •  go-up   go-down


42. Lai R: Survival of patients with adult medulloblastoma: a population-based study. Cancer; 2008 Apr 1;112(7):1568-74
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of patients with adult medulloblastoma: a population-based study.
  • BACKGROUND: Adult medulloblastoma accounts for less than 1% of adult intracranial tumors.
  • RESULTS: Four hundred fifty-four patients with adult medulloblastoma were diagnosed from 1973-2004 in the 17 regions covered by SEER.
  • [MeSH-major] Cerebellar Neoplasms / mortality. Medulloblastoma / mortality
  • [MeSH-minor] Adult. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Prognosis. Registries. SEER Program. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278809.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Privitera G, Acquaviva G, Ettorre GC, Spatola C: Antiangiogenic therapy in the treatment of recurrent medulloblastoma in the adult: case report and review of the literature. J Oncol; 2009;2009:247873

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiangiogenic therapy in the treatment of recurrent medulloblastoma in the adult: case report and review of the literature.
  • Medulloblastoma is a rare tumor in central nervous system, with an even rarer occurrence in adulthood.
  • We report the case of a 51-year-old man with recurrent medulloblastoma.
  • The aim of this report is to show that recurrent medulloblastoma in adults can be approached with a multimodality treatment and that antiangiogenic therapy should have a role in the management of this disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol. 2005 Mar;252(3):291-9 [16189725.001]
  • [Cites] J Clin Oncol. 1999 Mar;17(3):832-45 [10071274.001]
  • [Cites] Pediatr Res. 2008 May;63(5):584-90 [18427305.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):384-92 [17704359.001]
  • [Cites] Paediatr Drugs. 2007;9(2):81-96 [17407364.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):169-76 [9266455.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):690-8 [7931615.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):433-40 [1847194.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2465-9 [2249186.001]
  • [Cites] Eur J Cancer. 1990 Apr;26(4):464-9 [2141512.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):572-82 [2319316.001]
  • [Cites] J Clin Oncol. 2003 Apr 15;21(8):1581-91 [12697884.001]
  • (PMID = 20111585.001).
  • [ISSN] 1687-8469
  • [Journal-full-title] Journal of oncology
  • [ISO-abbreviation] J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2804042
  •  go-up   go-down


44. Herrlinger U, Steinbrecher A, Rieger J, Hau P, Kortmann RD, Meyermann R, Schabet M, Bamberg M, Dichgans J, Bogdahn U, Weller M: Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse. J Neurol; 2005 Mar;252(3):291-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse.
  • Adult medulloblastoma is a rare tumor with few retrospective studies published so far.
  • This study reports therapy and outcome in all adult (>or=16 years old) medulloblastoma (n=34) and supratentorial primitive neuroectodermal tumor (PNET) patients (n=2) treated in 2 neuro-oncological centers between 1976 and 2002.
  • In conclusion, adjuvant chemotherapy may prolong survival in adult medulloblastoma patients.
  • As in pediatric medulloblastoma patients, primary infiltration of the floor of the 4(th) ventricle indicates a poor prognosis.
  • [MeSH-major] Cerebellar Neoplasms / therapy. Medulloblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Analysis of Variance. Combined Modality Therapy. Demography. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Radiation. Drug Therapy / methods. Female. Humans. Male. Middle Aged. Radiotherapy, High-Energy / methods. Recurrence. Regression Analysis. Retrospective Studies. Risk Factors. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16189725.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


45. Sousa R, Sá G, Reimão S, Lopes L, Ruivo J, Albuquerque L, Campos J: [Adult cerebellar medulloblastoma: imaging findings in eight cases]. Acta Med Port; 2006 Nov-Dec;19(6):466-70
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult cerebellar medulloblastoma: imaging findings in eight cases].
  • Medulloblastoma is a brain tumor of neuroepithelial origin, frequent in children but rare in adults.
  • The imaging pattern is well studied in the pediatric group thought there is controversy about the imaging characteristics in adults.
  • We report CT and MRI imaging findings of 8 adult patients with cerebellar medulloblastoma.
  • The imaging findings of medulloblastomas in adults are unspecific and different from those in child.
  • They should be considered in the differential diagnosis of cerebellar tumor in adults, especially if they are hyperdense on CT, with well defined margins, with superficial extension and with dural involvement.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / radiography. Medulloblastoma / pathology. Medulloblastoma / radiography
  • [MeSH-minor] Adolescent. Adult. Cerebellum / pathology. Cerebellum / radiography. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17583605.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


46. Sauvageot CM, Kesari S, Stiles CD: Molecular pathogenesis of adult brain tumors and the role of stem cells. Neurol Clin; 2007 Nov;25(4):891-924, vii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of adult brain tumors and the role of stem cells.
  • Primary brain tumors consist of neoplasms with varied molecular defects, morphologic phenotypes, and clinical outcomes.
  • The genetic and signaling abnormalities involved in tumor initiation and progression of the most prevalent adult primary brain tumors, including gliomas, meningiomas, and medulloblastomas, are described in this article.
  • [MeSH-major] Brain Neoplasms / pathology. Stem Cells / pathology. Stem Cells / physiology
  • [MeSH-minor] Adult. Genes, p53 / genetics. Humans. Intercellular Signaling Peptides and Proteins / genetics. Phenotype. RNA, Messenger / genetics. Signal Transduction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964020.001).
  • [ISSN] 0733-8619
  • [Journal-full-title] Neurologic clinics
  • [ISO-abbreviation] Neurol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intercellular Signaling Peptides and Proteins; 0 / RNA, Messenger
  • [Number-of-references] 272
  •  go-up   go-down


47. Duggan A, Madathany T, de Castro SC, Gerrelli D, Guddati K, García-Añoveros J: Transient expression of the conserved zinc finger gene INSM1 in progenitors and nascent neurons throughout embryonic and adult neurogenesis. J Comp Neurol; 2008 Apr 01;507(4):1497-520
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient expression of the conserved zinc finger gene INSM1 in progenitors and nascent neurons throughout embryonic and adult neurogenesis.
  • INSM1 is a zinc-finger protein expressed in the developing nervous system and pancreas as well as in medulloblastomas and neuroendocrine tumors.
  • With in situ hybridization combined with immunohistochemistry, we detected INSM1 mRNA in all embryonic to adult neuroproliferative areas examined: embryonic neocortex, ganglionic eminence, midbrain, retina, hindbrain, and spinal cord; autonomic, dorsal root, trigeminal and spiral ganglia; olfactory and vomeronasal organ epithelia; postnatal cerebellum; and juvenile to adult subgranular zone of dentate gyrus, subventricular zone, and rostral migratory stream leading to olfactory bulb.
  • [MeSH-major] DNA-Binding Proteins / biosynthesis. Gene Expression Regulation, Developmental. Nervous System / embryology. Neurons / metabolism. Repressor Proteins / biosynthesis. Stem Cells / metabolism

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18205207.001).
  • [ISSN] 1096-9861
  • [Journal-full-title] The Journal of comparative neurology
  • [ISO-abbreviation] J. Comp. Neurol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G9826762; United Kingdom / Medical Research Council / / G9900837; United States / NINDS NIH HHS / NS / R01 NS044363
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins; 147955-03-1 / INSM1 protein, human
  •  go-up   go-down


48. Mittal P, Gupta K, Saggar K, Kaur S: Adult medulloblastoma mimicking Lhermitte-Duclos disease: can diffusion weighted imaging help? Neurol India; 2009 Mar-Apr;57(2):203-5
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult medulloblastoma mimicking Lhermitte-Duclos disease: can diffusion weighted imaging help?
  • Lhermitte-Duclos disease, also known as dysplastic cerebellar gangliocytoma, is a rare cerebellar benign tumor with characteristic appearance of thickened cerebellar folia giving a laminated or striated appearance, quite diagnostic of the condition.
  • We had seen a patient with medulloblastoma with imaging findings suspicious for thickened cerebellar folia reminiscent of Lhermitte-Duclos disease.
  • [MeSH-major] Cerebellar Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging. Hamartoma Syndrome, Multiple / diagnosis. Medulloblastoma / diagnosis
  • [MeSH-minor] Contrast Media. Humans. Magnetic Resonance Imaging. Male. Young Adult

  • Genetic Alliance. consumer health - Lhermitte-Duclos disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19439857.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


49. Poelen J, Bernsen HJ, Prick MJ: Metastatic medulloblastoma in an adult; treatment with temozolomide. Acta Neurol Belg; 2007 Jun;107(2):51-4
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic medulloblastoma in an adult; treatment with temozolomide.
  • Medulloblastoma is a malignant brain tumour most frequently seen in children.
  • Relapses of medulloblastoma are sensitive to chemotherapy and treatment with chemotherapeutics in children has increased the survival rates.
  • A medulloblastoma at adult age is extremely rare, and there is no overall accepted treatment, especially not in the case of a relapse.
  • This observation encouraged us to decide to treat an adult patient with a recurrent medulloblastoma with temozolomide.
  • This female patient showed a recurrence of a medulloblastoma 7 years after the initial presentation with metastatic spread along the neuraxis and progressive neurological deterioration.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Cerebellar Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Medulloblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Spinal Cord Neoplasms / drug therapy. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17710841.001).
  • [ISSN] 0300-9009
  • [Journal-full-title] Acta neurologica Belgica
  • [ISO-abbreviation] Acta Neurol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


50. Furtado SV, Venkatesh PK, Dadlani R, Reddy K, Hegde AS: Adult medulloblastoma and the "dural-tail" sign: rare mimic of a posterior petrous meningioma. Clin Neurol Neurosurg; 2009 Jul;111(6):540-3
Genetic Alliance. consumer health - Meningioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult medulloblastoma and the "dural-tail" sign: rare mimic of a posterior petrous meningioma.
  • The histological diagnosis was classical medulloblastoma.
  • We review literature of this atypical presentation of medulloblastoma and "dural-tail" sign, which can be associated with other benign or malignant lesions.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellopontine Angle / pathology. Dura Mater / pathology. Infratentorial Neoplasms / pathology. Medulloblastoma / pathology. Meningioma / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Spectroscopy. Male. Petrous Bone. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19285790.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 19
  •  go-up   go-down


51. Menon G, Krishnakumar K, Nair S: Adult medulloblastoma: clinical profile and treatment results of 18 patients. J Clin Neurosci; 2008 Feb;15(2):122-6
MedlinePlus Health Information. consumer health - Clinical Trials.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult medulloblastoma: clinical profile and treatment results of 18 patients.
  • The objective of this article is to examine the clinicoradiological features and surgical outcomes of adult patients (>16 years) with medulloblastoma.
  • An attempt was made to identify the predictors of poor outcome and assess patterns of relapse and to compare these with pediatric medulloblastoma.
  • Retrospective case record analyses were performed on 18 adults (>16 years) and 79 children (<16 years) operated upon after January 1990, who had at least 5 years of follow-up.
  • The tumor was located in the vermis in 12 patients (66.6%) and in the cerebellar hemisphere in six (16.6%).
  • In spite of recent advances in management, patients with medulloblastoma still have a poor prognosis.
  • However, adults fared better than children.
  • Vermian location had a better outcome in adults, but not in children.
  • Desmoplastic variant histology was not observed to be a significant prognostic factor in the adult group while brain stem invasion carried a poor prognosis.
  • [MeSH-major] Cerebellar Neoplasms / therapy. Clinical Trials as Topic. Medulloblastoma / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18078755.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


52. Brandes AA, Franceschi E, Tosoni A, Blatt V, Ermani M: Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer; 2007 Nov 1;110(9):2035-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term results of a prospective study on the treatment of medulloblastoma in adults.
  • BACKGROUND: Because medulloblastoma (MB) is rare in adults, the few studies on this condition have been retrospective, and the follow-up has tended to be short.
  • METHODS: In 1989, a prospective Phase II trial was initiated to evaluate the efficacy of treatment for adults with MB.
  • Patients were staged completely with a neuroradiologic examination of the brain and neuroaxis and by cerebrospinal fluid cytology, according to Chang's staging system.
  • RESULTS: After a median follow up of 7.6 years, among a total of 36 adults with MB, the overall progression-free survival (PFS) and overall survival (OS) rates at 5 years were 72% and 75%, respectively.
  • CONCLUSIONS: In adult patients with MB, long-term follow-up was essential for evaluating the real impact of treatments.
  • [MeSH-major] Cerebellar Neoplasms / drug therapy. Cerebellar Neoplasms / radiotherapy. Medulloblastoma / drug therapy. Medulloblastoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Prospective Studies. Radiotherapy. Survival Rate. Time. Treatment Outcome

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17823910.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Ueba T, Kadota E, Kano H, Yamashita K, Kageyama N: MATH-1 production by an adult medulloblastoma suggestive of a cerebellar external granule cell precursor origin. J Clin Neurosci; 2008 Jan;15(1):84-7
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MATH-1 production by an adult medulloblastoma suggestive of a cerebellar external granule cell precursor origin.
  • Radiological, histological and molecular findings in an uncommon adult case of cerebellar medulloblastoma suggested an external granular cell precursor origin.
  • Postoperative neuronal imaging studies showed that the tumor located in the cerebellar folia had been removed totally.
  • Pathological examination identified it as a desmoplastic medulloblastoma with subpial and subarachnoid infiltration and some infiltration into the molecular and granular layer via the perivascular space.
  • Polymerase chain reaction and immunohistochemical findings revealed the presence of MATH-1, expressed in cerebellar external granule cell precursors during fetal development, in the tumor cells.
  • These findings suggest that the tumor arose from external granule cell precursors of the cerebellum and that it was therefore of neuronal lineage.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Cerebellar Neoplasms / metabolism. Cerebellar Neoplasms / pathology. Medulloblastoma / metabolism. Medulloblastoma / pathology. Neurons / physiology
  • [MeSH-minor] Adult. Female. Gene Expression Regulation, Neoplastic. Humans. Magnetic Resonance Imaging / methods. Neoplastic Stem Cells / physiology. Phosphopyruvate Hydratase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18032051.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / ATOH1 protein, human; 0 / Basic Helix-Loop-Helix Transcription Factors; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


54. Yong RL, Kavanagh EC, Fenton D, Dorovini-Zis K, Heran MK, Haw CS: Midline cerebellar medulloblastoma in a seventy-one-year-old patient. Can J Neurol Sci; 2006 Feb;33(1):101-4
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Midline cerebellar medulloblastoma in a seventy-one-year-old patient.
  • BACKGROUND: Medulloblastoma is the most common malignant central nervous system tumour in children but, in contrast, quite rare in adults.
  • Hemispheric, rather than midline, cerebellar medulloblastomas are more common in older children and adults.
  • We present the unusual case of a 71-year-old man who presented with a fourth ventricular mass that proved to be a medulloblastoma.
  • A CT scan of the brain revealed a hyperattenuating, partially calcified, avidly enhancing mass within the fourth ventricle.
  • These findings were consistent with a classical medulloblastoma.
  • CONCLUSION: Adult medulloblastoma should be considered in the differential diagnosis of a partially calcified hyperattenuating mass within the fourth ventricle.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebral Ventricle Neoplasms / pathology. Medulloblastoma / pathology
  • [MeSH-minor] Aged. Brain Neoplasms / pathology. Diagnosis, Differential. Diffusion Magnetic Resonance Imaging. Fourth Ventricle / pathology. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Phosphopyruvate Hydratase / metabolism. Synaptophysin / metabolism. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583731.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


55. Hambardzumyan D, Becher OJ, Holland EC: Cancer stem cells and survival pathways. Cell Cycle; 2008 May 15;7(10):1371-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas and medulloblastomas are the most frequent malignant brain tumors in adult and children respectively.
  • Although both tumors arise in the CNS, there is a significant difference in their therapeutic response.
  • Medulloblastomas are relatively curable, while glioblastomas are basically incurable.
  • During the last decade several reports have demonstrated the existence of cancer stem cells in brain tumors, their location and their response to treatment.
  • We have recently described the therapeutic response of medulloblastomas to radiation in their native microenvironment, illustrating how p53 and Pi3K signaling pathways lead to the evasion of cell death by the nestin-expressing cells in the perivascular stem cell niche, even while the bulk of tumor succumbs to apoptosis.(1) It remains to be determined whether this mechanism of tumor resistance applies to the more complex stem-cell niche and tumor bulk of gliomas.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Medulloblastoma / radiotherapy. Neoplastic Stem Cells / radiation effects. Signal Transduction / radiation effects
  • [MeSH-minor] Animals. Humans. Intermediate Filament Proteins / metabolism. Mice. Models, Biological. Nerve Tissue Proteins / metabolism. Nestin. Phosphatidylinositol 3-Kinases / metabolism. Receptors, Notch / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18421251.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 5R01CA100688-2; United States / NCI NIH HHS / CA / R01CA 5R01CA099489-1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nes protein, mouse; 0 / Nestin; 0 / Receptors, Notch; 0 / Tumor Suppressor Protein p53; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  • [Number-of-references] 112
  •  go-up   go-down


56. Pruthi N, Devi BI, Shivshankar JJ, Pandey P: Abscess-a rare fourth ventricular mass. Acta Neurochir (Wien); 2007 Nov;149(11):1179-81; discussion 1181

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Midline posterior fossa mass lesions in young adults are usually medulloblastomas, pilocytic astrocytomas, haemangioblastomas or ependymomas.
  • [MeSH-major] Brain Abscess / surgery. Fourth Ventricle / surgery. Gram-Negative Bacterial Infections / surgery. Klebsiella Infections / surgery. Klebsiella oxytoca. Otitis Media, Suppurative / complications
  • [MeSH-minor] Adult. Chronic Disease. Diagnosis, Differential. Humans. Hydrocephalus / diagnosis. Hydrocephalus / surgery. Magnetic Resonance Imaging. Male. Mastoiditis / complications. Sinus Thrombosis, Intracranial / diagnosis. Tomography, X-Ray Computed. Ventriculoperitoneal Shunt

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17906968.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


57. Pizem J, Cör A, Zadravec Zaletel L, Popovic M: Prognostic significance of apoptosis in medulloblastoma. Neurosci Lett; 2005 Jun 10-17;381(1-2):69-73
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of apoptosis in medulloblastoma.
  • Since apoptosis is a major contributor to cell loss in medulloblastoma, either spontaneous or induced by radiation and chemotherapy, the apoptotic rate in resection specimens could have prognostic significance.
  • We analysed the apoptotic rate in 58 medulloblastoma resection specimens using an antibody against cleaved caspase 3, a specific marker of apoptotic cell death, and tested its possible prognostic significance.
  • The apoptotic rate varied considerably among medulloblastomas (0.1-25.9%, median 1.1%).
  • The apoptotic rate was higher in medulloblastomas with CSF dissemination, tended to be higher in desmoplastic medulloblastomas, but there was no association with age group and sex.
  • The variation in apoptotic rate among medulloblastomas is very likely predominantly associated with variations in tumour microenvironment, as supported by apoptotic cell clustering and rimming around necrotic areas.
  • The apoptotic rate in medulloblastoma resection specimens does not seem to be of prognostic value.
  • [MeSH-major] Apoptosis. Cerebellar Neoplasms / classification. Cerebellar Neoplasms / pathology. Medulloblastoma / classification. Medulloblastoma / pathology. Risk Assessment / methods
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882792.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


58. Bobola MS, Finn LS, Ellenbogen RG, Geyer JR, Berger MS, Braga JM, Meade EH, Gross ME, Silber JR: Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. Clin Cancer Res; 2005 Oct 15;11(20):7405-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors.
  • We assayed apurinic/apyrimidinic endonuclease activity in medulloblastomas and primitive neuroectodermal tumors (PNET) to establish correlates with tumor and patient characteristics and with response to adjuvant radiation plus multiagent chemotherapy.
  • EXPERIMENTAL DESIGN: Ap endo activity was assayed in 52 medulloblastomas and 10 PNETs from patients 0.4 to 21 years old.
  • Ape1/Ref-1, the predominant human Ap endo activity, was measured in 42 medulloblastomas by immunostaining.
  • Cox proportional hazards regression models were used to analyze the association of activity with time to tumor progression (TTP).
  • RESULTS: Tumor Ap endo activity varied 180-fold and was significantly associated with age and gender.
  • Tumor Ape1/Ref-1 was detected almost exclusively in nuclei.
  • In a multivariate model, with Ap endo activity entered as a continuous variable, the hazard ratio for progression after adjuvant treatment in 46 medulloblastomas and four PNETs increased by a factor of 1.073 for every 0.01 unit increase in activity (P < or = 0.001) and was independent of age and gender.
  • Suppressing Ap endo activity in a human medulloblastoma cell line significantly increased sensitivity to 1,3-bis(2-chlororethyl)-1-nitrosourea and temozolomide, suggesting that the association of tumor activity with TTP reflected, at least in part, abasic site repair.
  • CONCLUSIONS: Our data (a) suggest that Ap endo activity promotes resistance to radiation plus chemotherapy in medulloblastomas/PNETs, (b) provide a potential marker of treatment outcome, and (c) suggest clinical use of Ap endo inhibitors to overcome resistance.
  • [MeSH-major] Brain Neoplasms / enzymology. DNA-(Apurinic or Apyrimidinic Site) Lyase / metabolism. Medulloblastoma / enzymology. Neuroectodermal Tumors, Primitive / enzymology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents, Alkylating / pharmacology. Blotting, Western. Brain / drug effects. Brain / enzymology. Brain / radiation effects. Carmustine / pharmacology. Cell Line, Tumor. Cell Nucleus / enzymology. Cell Survival / drug effects. Cell Survival / genetics. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Dose-Response Relationship, Drug. Female. Humans. Immunohistochemistry. Infant. Infant, Newborn. Male. Multivariate Analysis. Oligonucleotides, Antisense / genetics. RNA, Small Interfering / genetics. Time Factors. Transfection

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16243814.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA104593; United States / NCI NIH HHS / CA / CA70790; United States / NCI NIH HHS / CA / CA82622
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Oligonucleotides, Antisense; 0 / RNA, Small Interfering; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase; U68WG3173Y / Carmustine
  •  go-up   go-down


59. Arai K, Sato N, Aoki J, Yagi A, Taketomi-Takahashi A, Morita H, Koyama Y, Oba H, Ishiuchi S, Saito N, Endo K: MR signal of the solid portion of pilocytic astrocytoma on T2-weighted images: is it useful for differentiation from medulloblastoma? Neuroradiology; 2006 Apr;48(4):233-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR signal of the solid portion of pilocytic astrocytoma on T2-weighted images: is it useful for differentiation from medulloblastoma?
  • BACKGROUND AND PURPOSE: Although imaging features of cerebellar pilocytic astrocytoma and medulloblastoma have been described in many texts, original comparisons of magnetic resonance intensity between these two tumours are limited.
  • METHODS: MR images of ten cerebellar pilocytic astrocytomas and ten medulloblastomas were reviewed.
  • No medulloblastomas showed such hyperintensity.
  • Most medulloblastomas (80%) were isointense to grey matter.
  • On T1-weighted images, the signal intensity varied widely in pilocytic astrocytomas; however, all medulloblastomas were iso- or hypointense to grey matter.
  • CONCLUSION: A signal intensity of the solid portion isointense to CSF on T2-weighted images was characteristic of cerebellar pilocytic astrocytomas; this was not observed in medulloblastomas.
  • Attention to T2-weighted imaging of the solid portions of a tumour is easy and helpful in differentiating between cerebellar pilocytic astrocytoma and medulloblastoma.
  • [MeSH-major] Astrocytoma / diagnosis. Cerebellar Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Medulloblastoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Male

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550430.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


60. Jacobs JF, Grauer OM, Brasseur F, Hoogerbrugge PM, Wesseling P, Gidding CE, van de Rakt MW, Figdor CG, Coulie PG, de Vries IJ, Adema GJ: Selective cancer-germline gene expression in pediatric brain tumors. J Neurooncol; 2008 Jul;88(3):273-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective cancer-germline gene expression in pediatric brain tumors.
  • Their expression has been studied in a wide range of human tumors in adults.
  • We measured the expression of 12 CGGs in pediatric brain tumors, to identify targets for therapeutic cancer vaccines.
  • Real Time PCR was used to quantify the expression of genes MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, MAGE-C2, NY-ESO-1 and GAGE-1,2,8 in 50 pediatric brain tumors of different histological subtypes.
  • Fifty-five percent of the medulloblastomas (n = 11), 86% of the ependymomas (n = 7), 40% of the choroid plexus tumors (n = 5) and 67% of astrocytic tumors (n = 27) expressed one or more CGGs.
  • With exception of a minority of tumors, the overall level of CGG expression in pediatric brain tumors was low.
  • CGG-encoded antigens are therefore suitable targets in a very selected group of pediatric patients with a brain tumor.
  • Interestingly, glioblastomas from adult patients expressed CGGs more often and at significantly higher levels compared to pediatric glioblastomas.
  • This observation is in line with the notion that pediatric and adult glioblastomas develop along different genetic pathways.
  • [MeSH-major] Brain Neoplasms / genetics. Gene Expression. Genes, Neoplasm
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Humans. Immunohistochemistry. Infant. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] In Vivo. 2002 Nov-Dec;16(6):583-8 [12494904.001]
  • [Cites] Immunol Rev. 2002 Oct;188:51-64 [12445281.001]
  • [Cites] Nat Rev Immunol. 2003 Jul;3(7):569-81 [12876559.001]
  • [Cites] Clin Neuropathol. 2003 Jul-Aug;22(4):180-6 [12908754.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):3-11 [12952281.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):777-84 [17957795.001]
  • [Cites] Int Rev Immunol. 2003 Mar-Apr;22(2):113-40 [12962272.001]
  • [Cites] Science. 1991 Dec 13;254(5038):1643-7 [1840703.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):527-8 [8509230.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1004-8 [8302824.001]
  • [Cites] Annu Rev Immunol. 1994;12:337-65 [8011285.001]
  • [Cites] Neurosurgery. 1994 Jun;34(6):967-72; discussion 972-3 [8084407.001]
  • [Cites] N Engl J Med. 1995 Jan 19;332(3):143-9 [7800006.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2236-9 [7757970.001]
  • [Cites] Mod Pathol. 1995 Apr;8(3):333-8 [7617661.001]
  • [Cites] Ther Immunol. 1995 Jun;2(3):173-81 [8885135.001]
  • [Cites] Am J Pathol. 1997 Jun;150(6):2143-52 [9176405.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Jul;56(7):782-9 [9210874.001]
  • [Cites] Biotechniques. 1997 Sep;23(3):456-60 [9298216.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8 [10379968.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Neurol Res. 2005 Oct;27(7):692-702 [16197806.001]
  • [Cites] Int J Cancer. 2007 Jan 1;120(1):67-74 [17019710.001]
  • [Cites] Cancer Immunol Immunother. 2007 Feb;56(2):259-69 [16758204.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):988-99; discussioin 999-1000 [17143233.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Exp Med. 2007 Sep 3;204(9):2023-30 [17682068.001]
  • [Cites] Int J Oncol. 2000 Jan;16(1):81-96 [10601552.001]
  • [Cites] Int J Cancer. 2000 Jun 15;86(6):835-41 [10842198.001]
  • [Cites] Transplantation. 2000 Jun 15;69(11):2366-73 [10868642.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3916-22 [11051238.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1525-32 [11290570.001]
  • [Cites] Int J Cancer. 2001 Jun 15;92(6):856-60 [11351307.001]
  • [Cites] Nature. 2001 May 17;411(6835):380-4 [11357146.001]
  • [Cites] Clin Chem. 2002 Jan;48(1):25-34 [11751535.001]
  • [Cites] Vaccine. 2003 Jan 30;21(7-8):781-6 [12531359.001]
  • (PMID = 18398575.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC2440921
  •  go-up   go-down


61. McCabe MG, Ichimura K, Pearson DM, Liu L, Clifford SC, Ellison DW, Collins VP: Novel mechanisms of gene disruption at the medulloblastoma isodicentric 17p11 breakpoint. Genes Chromosomes Cancer; 2009 Feb;48(2):121-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel mechanisms of gene disruption at the medulloblastoma isodicentric 17p11 breakpoint.
  • Isodicentric 17q is the most commonly reported chromosomal abnormality in medulloblastomas.
  • Its frequency suggests that genes disrupted in medulloblastoma formation may play a role in tumorigenesis.
  • CGH with a custom tiling path genomic BAC array of chromosome 17 enriched with fosmids at the breakpoint regions was used to analyze a series of 45 medulloblastomas and three medulloblastoma-derived cell lines.
  • In total, 17 of 45 medulloblastomas had an isodicentric 17q.
  • [MeSH-major] Chromosome Breakage. Chromosomes, Human, Pair 17 / genetics. Medulloblastoma / genetics
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Chromosome Mapping. Comparative Genomic Hybridization. Female. Gene Deletion. Gene Dosage. Gene Duplication. Humans. Male. Oligonucleotide Array Sequence Analysis. Recombination, Genetic

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18973140.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Rumboldt Z, Camacho DL, Lake D, Welsh CT, Castillo M: Apparent diffusion coefficients for differentiation of cerebellar tumors in children. AJNR Am J Neuroradiol; 2006 Jun-Jul;27(6):1362-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Brain MR imaging studies that included ADC maps were retrospectively reviewed in 32 patients with histologically proved cerebellar neoplasm.
  • There were 17 juvenile pilocytic astrocytomas (JPA), 8 medulloblastomas, 5 ependymomas, and 2 rhabdoid (atypical teratoid/rhabdoid tumor [AT/RT]) tumors.
  • Absolute ADC values of contrast-enhancing solid tumor regions and ADC ratios (ADC of solid tumor to ADC of normal-appearing white matter) were compared with the histologic diagnosis.
  • ADC values and ratios of JPAs, medulloblastomas, and ependymomas were compared by using a 2-tailed t test and one-way analysis of variance (ANOVA).
  • RESULTS: ADC values were significantly higher in pilocytic astrocytomas (1.65 +/- 0.27) (mean +/- SD) than in ependymomas (1.10 +/- 0.11) (P = .0003) and medulloblastomas (0.66 +/- 0.15) (P < .0001).
  • Ependymomas demonstrated significantly higher ADC values than medulloblastomas (P = .0005).
  • ADC ratios were also significantly different among these 3 tumor types.
  • AT/RT ADC values were similar to medulloblastoma.
  • The range of ADC values and ratios within JPAs and ependymomas did not overlap with that of medulloblastomas.
  • CONCLUSION: Assessment of ADC values of enhancing solid tumor is a simple and reliable technique for preoperative differentiation of cerebellar tumors in pediatric patients.
  • Our cutoff values of >1.4 x 10(3) mm(2)/s for JPA and <0.9 x 10(3) mm(2)/s for medulloblastoma were 100% specific.
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / diagnosis. Astrocytoma / pathology. Child. Child, Preschool. Diagnosis, Differential. Ependymoma / diagnosis. Ependymoma / pathology. Female. Humans. Infant. Male. Medulloblastoma / diagnosis. Medulloblastoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Neurol. 2007 Feb;3(2):78-9 [17279080.001]
  • (PMID = 16775298.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Liu JG, Liu YH, Cai J, Liu XS, Song WZ, Huang Y, Mao Q: [Expression of epidermal growth factor receptor and PTEN in malignancy brain tumors]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Nov;37(6):868-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of epidermal growth factor receptor and PTEN in malignancy brain tumors].
  • OBJECTIVE: To detect and analysis epidermal growth factor receptor (EGFR) and phosphatase and tensin homolog deleted on chromosome ten (PTEN) in different malignancy brain tumors, and to evaluate their prognostic significance.
  • METHODS: Using immunohistochemistry to detect the expression of EGFR and PTEN and adopting confocal technology to verify their location in the specimens of 25 respectively glioblastoma multiformes, medulloblastomas, anaplastic oligodendrogliomas, and anaplastic ependymomas.
  • However amplification of EGFR and deletion of PTEN were relatively low in other malignancy brain tumors.
  • They were 36% and 8% in medulloblastomas, and 28% and 8% in anaplastic oligodendrogliomas, and 24% and 4% in anaplastic ependymomas.
  • PTEN mutation and EGFR overexpression are rare in medulloblastoma, anaplastic oligodendroglioma, and anaplastic ependymoma, so the EGFR or PTEN targeted antitumor approaches may be useful in glioblastoma multiformes but the other 3 tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Gene Expression Regulation, Neoplastic. PTEN Phosphohydrolase / metabolism. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236582.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


64. Roussos I, Balaña C, Cuadras P, Ballester R, Etxaniz O, Hostalot C: Medulloblastoma in young adults. Must we give adjuvant chemotherapy? Clin Transl Oncol; 2007 Feb;9(2):121-3
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medulloblastoma in young adults. Must we give adjuvant chemotherapy?
  • Medulloblastoma is a rare entity in adult patients.
  • Reports of medulloblastoma in adults are scarce but in all of them the prognosis seems similar to the prognosis of children.
  • We present our experience in five cases of medulloblastoma in young adults, treated at the University Hospital "Germans Trias i Pujol" from June 1994 to October 2003.
  • We have reviewed the literature, concluding that we have to adapt the findings in children to our adult patients, offering them adjuvant chemotherapy after surgery.
  • [MeSH-major] Cerebellar Neoplasms / drug therapy. Medulloblastoma / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17329226.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


65. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, Kranenburg TA, Hogg T, Poppleton H, Martin J, Finkelstein D, Pounds S, Weiss A, Patay Z, Scoggins M, Ogg R, Pei Y, Yang ZJ, Brun S, Lee Y, Zindy F, Lindsey JC, Taketo MM, Boop FA, Sanford RA, Gajjar A, Clifford SC, Roussel MF, McKinnon PJ, Gutmann DH, Ellison DW, Wechsler-Reya R, Gilbertson RJ: Subtypes of medulloblastoma have distinct developmental origins. Nature; 2010 Dec 23;468(7327):1095-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subtypes of medulloblastoma have distinct developmental origins.
  • Medulloblastoma encompasses a collection of clinically and molecularly diverse tumour subtypes that together comprise the most common malignant childhood brain tumour.
  • The pathological processes that drive heterogeneity among the other medulloblastoma subtypes are not known, hindering the development of much needed new therapies.
  • Here we provide evidence that a discrete subtype of medulloblastoma that contains activating mutations in the WNT pathway effector CTNNB1 (hereafter, WNT subtype) arises outside the cerebellum from cells of the dorsal brainstem.
  • We found that genes marking human WNT-subtype medulloblastomas are more frequently expressed in the lower rhombic lip (LRL) and embryonic dorsal brainstem than in the upper rhombic lip (URL) and developing cerebellum.
  • These lesions persisted in all mutant adult mice; moreover, in 15% of cases in which Tp53 was concurrently deleted, they progressed to form medulloblastomas that recapitulated the anatomy and gene expression profiles of human WNT-subtype medulloblastoma.
  • We provide the first evidence, to our knowledge, that subtypes of medulloblastoma have distinct cellular origins.
  • Our data provide an explanation for the marked molecular and clinical differences between SHH- and WNT-subtype medulloblastomas and have profound implications for future research and treatment of this important childhood cancer.

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1173-8 [19726761.001]
  • [Cites] Curr Opin Cell Biol. 2009 Dec;21(6):741-7 [19883998.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 May 4;107(18):8422-7 [20400693.001]
  • [Cites] Nature. 2010 Jul 29;466(7306):632-6 [20639864.001]
  • [Cites] EMBO J. 1999 Nov 1;18(21):5931-42 [10545105.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):513-6 [11212243.001]
  • [Cites] Hum Mol Genet. 2001 Jun 1;10(12):1325-34 [11406614.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):418-25 [11694875.001]
  • [Cites] Science. 2002 Jul 19;297(5580):365-9 [12130776.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5428-37 [14500378.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):229-40 [15380514.001]
  • [Cites] Science. 1997 Aug 22;277(5329):1109-13 [9262482.001]
  • [Cites] Development. 2005 May;132(10):2425-39 [15843415.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7951-7 [16258095.001]
  • [Cites] Genes Dev. 2005 Nov 15;19(22):2656-67 [16260494.001]
  • [Cites] Neuron. 2005 Dec 22;48(6):933-47 [16364898.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1924-31 [16567768.001]
  • [Cites] Neuron. 2006 Apr 20;50(2):205-18 [16630833.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]
  • [Cites] J Neurosci. 2006 Nov 22;26(47):12226-36 [17122047.001]
  • [Cites] Annu Rev Pathol. 2008;3:341-65 [18039127.001]
  • [Cites] Cell Stem Cell. 2007 Oct 11;1(4):443-57 [18371380.001]
  • [Cites] Cancer Cell. 2008 Aug 12;14(2):123-34 [18691547.001]
  • [Cites] Cancer Cell. 2008 Aug 12;14(2):135-45 [18691548.001]
  • [Cites] PLoS One. 2008;3(8):e3088 [18769486.001]
  • [Cites] Development. 2009 Jan;136(2):295-305 [19088088.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1880-5 [19164512.001]
  • [Cites] Neuroscience. 2009 Sep 1;162(3):560-73 [19303920.001]
  • [CommentIn] Nat Rev Cancer. 2011 Feb;11(2):79 [21322837.001]
  • [CommentIn] Nat Rev Cancer. 2011 Feb;11(2):80 [21436788.001]
  • (PMID = 21150899.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE24628
  • [Grant] United States / NCI NIH HHS / CA / R01 CA129541-04; United States / NCI NIH HHS / CA / R01 CA129541; United States / NCI NIH HHS / CA / R01CA129541; United States / NINDS NIH HHS / NS / R01 NS037956; United States / NCI NIH HHS / CA / R01 CA129541-02; United States / NCI NIH HHS / CA / R01 CA129541-05; United States / NCI NIH HHS / CA / R01 CA129541-03; United States / NCI NIH HHS / CA / P30CA021765; United States / NCI NIH HHS / CA / 01CA96832; United States / NCI NIH HHS / CA / P01 CA096832-06A18120; United States / NCI NIH HHS / CA / CA096832-078120; United States / NCI NIH HHS / CA / R01 CA129541-01; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P01 CA096832; United States / NINDS NIH HHS / NS / R01 NS037956-13; United States / NCI NIH HHS / CA / CA096832-06A18120; United States / NCI NIH HHS / CA / P01 CA096832-078120
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CTNNB1 protein, mouse; 0 / beta Catenin
  • [Other-IDs] NLM/ NIHMS245937; NLM/ PMC3059767
  •  go-up   go-down


66. Tanabe R, Fujii K, Miyashita T, Uchikawa H, Endo M, Sugita K, Arai H, Kohno Y: [Clinical manifestations in 25 Japanese patients with Gorlin syndrome]. No To Hattatsu; 2009 Jul;41(4):253-7
Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Compared with the previous studies in the United States, the United Kingdom, and Australia, Japanese Gorlin syndrome patients showed a significantly lower rate of BCCs, and no medulloblastomas in this study.
  • [MeSH-minor] Adolescent. Adult. Aged. Asian Continental Ancestry Group. Child. Child, Preschool. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19618879.001).
  • [ISSN] 0029-0831
  • [Journal-full-title] No to hattatsu. Brain and development
  • [ISO-abbreviation] No To Hattatsu
  • [Language] jpn
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


67. Nakahara Y, Northcott PA, Li M, Kongkham PN, Smith C, Yan H, Croul S, Ra YS, Eberhart C, Huang A, Bigner D, Grajkowska W, Van Meter T, Rutka JT, Taylor MD: Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma. Neoplasia; 2010 Jan;12(1):20-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic and epigenetic inactivation of Kruppel-like factor 4 in medulloblastoma.
  • Although medulloblastoma is the most common pediatric malignant brain tumor, its molecular underpinnings are largely unknown.
  • We have identified rare, recurrent homozygous deletions of Kruppel-like Factor 4 (KLF4) in medulloblastoma using high-resolution single nucleotide polymorphism arrays, digital karyotyping, and genomic real-time polymerase chain reaction (PCR).
  • Furthermore, we show that there is loss of physiological KLF4 expression in more than 40% of primary medulloblastomas both at the RNA and protein levels.
  • Medulloblastoma cell lines drastically increase the expression of KLF4 in response to the demethylating agent 5-azacytidine and demonstrate dense methylation of the promoter CpG island by bisulfite sequencing.
  • Methylation-specific PCR targeting the KLF4 promoter demonstrates CpG methylation in approximately 16% of primary medulloblastomas.
  • Reexpression of KLF4 in the D283 medulloblastoma cell line results in significant growth suppression both in vitro and in vivo.
  • We conclude that KLF4 is inactivated by either genetic or epigenetic mechanisms in a large subset of medulloblastomas and that it likely functions as a tumor suppressor gene in the pathogenesis of medulloblastoma.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Epigenesis, Genetic. Kruppel-Like Transcription Factors / genetics. Medulloblastoma / genetics
  • [MeSH-minor] Adult. Animals. Antimetabolites, Antineoplastic / pharmacology. Azacitidine / pharmacology. Cell Line, Tumor. CpG Islands / genetics. DNA Methylation / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Humans. Kaplan-Meier Estimate. Loss of Heterozygosity. Mice. Mice, Nude. Neoplasms, Experimental / genetics. Neoplasms, Experimental / pathology. Oligonucleotide Array Sequence Analysis. Polymorphism, Single Nucleotide. Promoter Regions, Genetic / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuron. 2001 Aug 30;31(4):557-68 [11545715.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3249-55 [19351822.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):395-402 [14724568.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2709-19 [15102675.001]
  • [Cites] Oncogene. 2004 Apr 22;23(19):3444-53 [15064731.001]
  • [Cites] Neoplasia. 2004 Mar-Apr;6(2):168-78 [15140406.001]
  • [Cites] Oncogene. 2004 Jun 3;23(26):4577-83 [15077159.001]
  • [Cites] Neoplasia. 2004 Jul-Aug;6(4):310-22 [15256053.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6002-9 [15342380.001]
  • [Cites] Development. 1999 May;126(9):1927-35 [10101126.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7787-93 [15520184.001]
  • [Cites] Cancer Res. 2005 Feb 1;65(3):919-24 [15705891.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4542-7 [15761058.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2746-54 [15805274.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):575-84 [16036108.001]
  • [Cites] Nat Cell Biol. 2005 Nov;7(11):1074-82 [16244670.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):11-23 [16372018.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1924-31 [16567768.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11579-83 [16864777.001]
  • [Cites] Lancet Oncol. 2006 Oct;7(10):813-20 [17012043.001]
  • [Cites] Childs Nerv Syst. 2006 Nov;22(11):1379-94 [16951964.001]
  • [Cites] Br J Cancer. 2007 Jul 16;97(2):267-74 [17579622.001]
  • [Cites] Cancer Res. 2007 Aug 1;67(15):7147-54 [17671182.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4679-84 [17878366.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 18;104(38):14935-40 [17846424.001]
  • [Cites] Neoplasia. 2008 Jan;10(1):89-98 [18231642.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4631-9 [18559508.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):736-44 [18592012.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16224-9 [18852474.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9945-53 [19047176.001]
  • [Cites] Neoplasia. 2008 Dec;10(12):1343-9, 5p following 1349 [19048113.001]
  • [Cites] Neuro Oncol. 2008 Dec;10(6):981-94 [18664619.001]
  • [Cites] Neoplasia. 2009 Jan;11(1):96-101 [19107236.001]
  • [Cites] Mol Cancer Res. 2009 Jan;7(1):33-40 [19147535.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2009 Mar;296(3):G490-8 [19109406.001]
  • [Cites] Nat Genet. 2009 Apr;41(4):465-72 [19270706.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):719-24 [19360079.001]
  • [Cites] Neoplasia. 2003 May-Jun;5(3):198-204 [12869303.001]
  • (PMID = 20072650.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS055089
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / GKLF protein; 0 / Kruppel-Like Transcription Factors; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC2805880
  •  go-up   go-down


68. Pizem J, Cört A, Zadravec-Zaletel L, Popovic M: Survivin is a negative prognostic marker in medulloblastoma. Neuropathol Appl Neurobiol; 2005 Aug;31(4):422-8
Genetic Alliance. consumer health - Medulloblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin is a negative prognostic marker in medulloblastoma.
  • Our aim was to analyse survivin expression in medulloblastoma, its association with aberrant activation of the WNT (wingless) pathway and to test the prognostic significance of survivin expression.
  • We immuno histochemically analysed survivin expression and localization of beta-catenin, a downstream mediator of the WNT pathway, in 56 cases of medulloblastoma.
  • Survivin expression tended to be higher in medulloblastomas with an aberrant activation of the WNT pathway (nuclear localization of beta-catenin), but did not correlate with histological type, age group or dissemination via cerebrospinal fluid pathways.
  • Survivin expression and dissemination status were two independent negative prognostic variables for the overall survival of patients with medulloblastoma.
  • In conclusion, survivin is up-regulated in medulloblastomas.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cerebellar Neoplasms / metabolism. Medulloblastoma / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cytoskeletal Proteins / metabolism. Female. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Prognosis. Survival Analysis. Trans-Activators / metabolism. Up-Regulation. beta Catenin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008826.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


69. Spreafico F, Massimino M, Gandola L, Cefalo G, Mazza E, Landonio G, Pignoli E, Poggi G, Terenziani M, Pedrazzoli P, Siena S, Fossati-Bellani F: Survival of adults treated for medulloblastoma using paediatric protocols. Eur J Cancer; 2005 Jun;41(9):1304-10
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of adults treated for medulloblastoma using paediatric protocols.
  • We retrospectively studied 26 consecutive adults treated for medulloblastoma using paediatric protocols.
  • Although the number of patients is limited, our data suggest that the sandwich sequential, moderately intensive chemotherapy in combination with HART is an effective treatment for medulloblastoma in adults, and this approach seems to overcome previously-recognised risk factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebellar Neoplasms / drug therapy. Medulloblastoma / drug therapy
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Chemotherapy, Adjuvant / methods. Cranial Irradiation / methods. Disease-Free Survival. Humans. Infusions, Intravenous. Lomustine / administration & dosage. Lomustine / adverse effects. Methotrexate / administration & dosage. Methotrexate / adverse effects. Middle Aged. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / mortality. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Medulloblastoma.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869875.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


70. Bal MM, Das Radotra B, Srinivasan R, Sharma SC: Does c-erbB-2 expression have a role in medulloblastoma prognosis? Indian J Pathol Microbiol; 2006 Oct;49(4):535-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does c-erbB-2 expression have a role in medulloblastoma prognosis?
  • The prognosis of patients with medulloblastoma has remained same for the last two decades.
  • This study evaluated the role of c-erbB-2 expression in medulloblastoma as a prognostic marker.
  • Fifty cases of medulloblastomas were investigated for the expression of c-erbB-2 protein using immunohistochemistry.
  • The mean DFS in c-erbB-2 positive cases was 19.81 months compared to 48.33 months in c-erbB-2 negative cases. c-erbB-2 positivity was found to be an independent predictor of poor outcome in medulloblastoma (p value < 0.05).
  • [MeSH-major] Medulloblastoma / diagnosis. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Prognosis. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-4

  • Genetic Alliance. consumer health - Medulloblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17183845.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB4 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-4
  •  go-up   go-down


71. Svärd J, Rozell B, Toftgård R, Teglund S: Tumor suppressor gene co-operativity in compound Patched1 and suppressor of fused heterozygous mutant mice. Mol Carcinog; 2009 May;48(5):408-19
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor suppressor gene co-operativity in compound Patched1 and suppressor of fused heterozygous mutant mice.
  • Dysregulation of the Hedgehog signaling pathway is central to the development of certain tumor types, including medulloblastoma and basal cell carcinoma (BCC).
  • Patched1 (Ptch1) and Suppressor of fused (Sufu) are two essential negative regulators of the pathway with tumor suppressor activity.
  • Ptch1(+/-) mice are predisposed to developing medulloblastoma and rhabdomyosarcoma, while Sufu(+/-) mice develop a skin phenotype characterized by basaloid epidermal proliferations.
  • Here, we have studied tumor development in Sufu(+/-)Ptch1(+/-) mice to determine the effect of compound heterozygosity on the onset, incidence, and spectrum of tumors.
  • For medulloblastoma, the cumulative 1-yr incidence was 1.5-fold higher in Sufu(+/-)Ptch1(+/-) compared to Ptch1(+/-) female mice but this strong trend was not statistically significant.
  • Together this suggests a weak genetic interaction of the two tumor suppressor genes.
  • Interestingly, most of the medulloblastomas from the Sufu(+/-)Ptch1(+/-) mice had lost expression of the remaining Ptch1 wild-type allele but not the Sufu wild-type allele.
  • On the contrary, Sufu as well as Gli1 and Gli2 expression was upregulated in the medulloblastomas compared to adult cerebellum in Ptch1(+/-) and Sufu(+/-)Ptch1(+/-) mice.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Oncogene. 2002 Oct 24;21(49):7580-4 [12386820.001]
  • [Cites] Cancer Cell. 2004 Sep;6(3):229-40 [15380514.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Oct;30(5):532-9 [15488029.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Science. 1997 Aug 22;277(5329):1109-13 [9262482.001]
  • [Cites] Nat Med. 1998 May;4(5):619-22 [9585239.001]
  • [Cites] Development. 1999 Oct;126(20):4431-40 [10498679.001]
  • [Cites] Genet Med. 2004 Nov-Dec;6(6):530-9 [15545751.001]
  • [Cites] Development. 2005 May;132(10):2425-39 [15843415.001]
  • [Cites] Development. 2005 Oct;132(19):4407-17 [16155214.001]
  • [Cites] J Pathol. 2006 Jan;208(1):17-25 [16294371.001]
  • [Cites] Dev Cell. 2006 Feb;10(2):187-97 [16459298.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2081-8 [16489008.001]
  • [Cites] PLoS Biol. 2006 Apr;4(4):e86 [16602821.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6964-71 [16849540.001]
  • [Cites] Oncogene. 2006 Sep 7;25(40):5575-80 [16636673.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10171-8 [17047082.001]
  • [Cites] Nat Rev Genet. 2006 Nov;7(11):841-50 [17047684.001]
  • [Cites] Nat Clin Pract Oncol. 2007 May;4(5):295-304 [17464337.001]
  • [Cites] Nat Cell Biol. 2007 Sep;9(9):1005-9 [17762891.001]
  • [Cites] Oncogene. 2007 Sep 27;26(44):6442-7 [17452975.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1285-91 [10545995.001]
  • [Cites] Nat Cell Biol. 1999 Sep;1(5):312-9 [10559945.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2239-46 [10786690.001]
  • [Cites] J Biol Chem. 2000 Sep 15;275(37):28341-4 [10884376.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):513-6 [11212243.001]
  • [Cites] Genes Dev. 2001 Dec 1;15(23):3059-87 [11731473.001]
  • [Cites] Nat Genet. 2002 Jul;31(3):306-10 [12068298.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • (PMID = 18781608.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA105491-06; United States / NCI NIH HHS / CA / U01 CA105491; United States / NCI NIH HHS / CA / U01 CA105491-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Cell Surface; 0 / Repressor Proteins; 0 / SUFU protein, human; 0 / patched receptors
  • [Other-IDs] NLM/ NIHMS77932; NLM/ PMC2674531
  •  go-up   go-down


72. Nern C, Sommerlad D, Acker T, Plate KH: Brain tumor stem cells. Recent Results Cancer Res; 2009;171:241-59
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor stem cells.
  • The dogma that solid tumors are composed of tumor cells that all share the same ability to produce proliferating daughter cells has been challenged in recent years.
  • There is growing evidence that many adult tissues contain a set of tissue stem cells, which might undergo malignant transformation while retaining their stem cell characteristics.
  • Brain tumors such as medulloblastomas or glioblastomas often contain areas of divergent differentiation, which raises the intriguing question of whether these tumors could derive from neural stem cells (NSCs).This chapter reviews the current knowledge of NSCs and relates them to brain tumor pathology.
  • Current therapy protocols for malignant brain tumors are targeted toward the reduction of bulk tumor mass.
  • The concept of brain-tumor stem cells could provide new insights for future therapies, if the capacity for self-renewal of tumor cells and growth of the tumor mass would reside within a small subset of cancer cells.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplastic Stem Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322548.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Peptides
  • [Number-of-references] 117
  •  go-up   go-down


73. Nicoletti F, Arcella A, Iacovelli L, Battaglia G, Giangaspero F, Melchiorri D: Metabotropic glutamate receptors: new targets for the control of tumor growth? Trends Pharmacol Sci; 2007 May;28(5):206-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabotropic glutamate receptors: new targets for the control of tumor growth?
  • Transformed neural stem-progenitor cells of the brain subventricular zone and the external granular layer of the cerebellum are the putative cells of origin of malignant gliomas and medulloblastomas, which are the most frequent malignant brain tumors in adults and children, respectively.
  • The proliferation of neural stem-progenitor cells is regulated by metabotropic glutamate (mGlu) receptors, which are G-protein-coupled receptors that are activated by glutamate, the major excitatory neurotransmitter of the CNS.
  • At least two receptor subtypes - mGlu(3) and mGlu(4) receptors - control the proliferation of brain tumor cells, whereas mGlu(1) receptors have been implicated in the development of melanomas.
  • We believe that individual mGlu receptor subtypes represent new potential targets for the treatment of several malignant tumors, including brain tumors.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Brain Neoplasms / drug therapy. Drug Delivery Systems. Receptors, Metabotropic Glutamate / drug effects
  • [MeSH-minor] Adult. Animals. Cell Proliferation. Child. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / physiopathology. Drug Resistance, Neoplasm. Gene Expression. Humans. Ligands. Melanoma / drug therapy. Melanoma / physiopathology. Neoplastic Stem Cells / drug effects. Skin Neoplasms / drug therapy. Skin Neoplasms / physiopathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433452.001).
  • [ISSN] 0165-6147
  • [Journal-full-title] Trends in pharmacological sciences
  • [ISO-abbreviation] Trends Pharmacol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ligands; 0 / Receptors, Metabotropic Glutamate
  •  go-up   go-down


74. Hu WW, Zheng XJ, Shen G, Liu WG, Shen H, Fu WM, Zhou JY: [Diagnosis and micro-neurosurgery for the fourth cerebral ventricle tumors]. Zhonghua Zhong Liu Za Zhi; 2007 Feb;29(2):144-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tumor of the fourth ventricle was clinically diagnosed in 86 patients basing on the preliminary assessment of symptom and CT or MRI findings.
  • The pathology included 32 medulloblastomas, 23 ependymoma, 15 astrocytoma, 10 hemangiblastomas, 2 choroid plexus papillomas, and 4 epidermoid cysts.
  • CONCLUSION: Medulloblastoma, astrocytoma and hemangiblastoma are suggested to be removed totally whenever technically possible according to the site, character and volume of the tumor.
  • For ependymoma, if close to the brain stem, is recommended to be subtotally removed.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Fourth Ventricle / pathology. Medulloblastoma / diagnosis. Microsurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / diagnosis. Astrocytoma / radiography. Astrocytoma / surgery. Child. Child, Preschool. Combined Modality Therapy. Ependymoma / diagnosis. Ependymoma / radiography. Ependymoma / surgery. Female. Follow-Up Studies. Hemangioblastoma / diagnosis. Hemangioblastoma / radiography. Hemangioblastoma / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis. Survival Rate. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645855.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


75. Viana-Pereira M, Almeida I, Sousa S, Mahler-Araújo B, Seruca R, Pimentel J, Reis RM: Analysis of microsatellite instability in medulloblastoma. Neuro Oncol; 2009 Oct;11(5):458-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of microsatellite instability in medulloblastoma.
  • Medulloblastoma is the most common malignant brain tumor in children.
  • The presence of microsatellite instability (MSI) in brain tumors, particularly medulloblastomas, has not been properly addressed.
  • The aim of the present study was to evaluate the role of MSI in medulloblastoma carcinogenesis.
  • This study is the most comprehensive analysis of MSI in medulloblastomas to date.
  • We observed the presence of MSI together with mutations of MSI target genes in a small fraction of cases, suggesting a new genetic pathway for a role in medulloblastoma development.
  • [MeSH-major] Biomarkers, Tumor / genetics. Cerebellar Neoplasms / genetics. Medulloblastoma / genetics. Microsatellite Instability
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. DNA Methylation. DNA Mutational Analysis. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Young Adult

  • Genetic Alliance. consumer health - Medulloblastoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Genet. 2002 Apr-Jun;45(2):71-5 [12119215.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4863-71 [12101426.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5738-44 [14522894.001]
  • [Cites] Cancer. 2003 Nov 15;98(10):2199-206 [14601090.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):209-18 [15050952.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1982 Nov;8(11):2023-7 [6759487.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):152-6 [8162069.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23):5545-7 [7585631.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 1;84(1):56-9 [7497444.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4749-56 [9354436.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):896-9 [9500446.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1415-9 [9626457.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):294-7 [9927034.001]
  • [Cites] Oncol Res. 1998;10(8):421-8 [10100759.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2995-3002 [10383166.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3346-51 [10416591.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4213-5 [10485457.001]
  • [Cites] Dis Markers. 2004;20(4-5):251-7 [15528790.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Feb;131(2):87-93 [15672285.001]
  • [Cites] Acta Neuropathol. 2005 Feb;109(2):207-10 [15791479.001]
  • [Cites] Ann Hematol. 2005 Jun;84(6):368-75 [15789228.001]
  • [Cites] Nucleic Acids Res. 2005;33(14):e128 [16106041.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):241-51 [16330668.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2113-8 [16288216.001]
  • [Cites] Carcinogenesis. 2006 May;27(5):951-5 [16490738.001]
  • [Cites] Virchows Arch. 2006 Aug;449(2):238-43 [16639607.001]
  • [Cites] Cancer Biomark. 2006;2(1-2):69-86 [17192061.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Feb;4(2):130-4 [17259933.001]
  • [Cites] Br J Cancer. 2007 Feb 26;96(4):660-6 [17285135.001]
  • [Cites] Brain Pathol. 2007 Apr;17(2):146-50 [17388945.001]
  • [Cites] Cancer. 2007 Jun 1;109(11):2349-56 [17440981.001]
  • [Cites] Eur J Hum Genet. 2007 Sep;15(9):922-9 [17534377.001]
  • [Cites] J Cancer Res Clin Oncol. 2007 Oct;133(10):749-59 [17530287.001]
  • [Cites] Oncogene. 2007 Aug 30;26(40):5919-26 [17384679.001]
  • [Cites] Lab Invest. 2007 Oct;87(10):1055-65 [17700563.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Dec;46(12):1061-8 [17879369.001]
  • [Cites] DNA Repair (Amst). 2008 Feb 1;7(2):321-8 [18162445.001]
  • [Cites] J Clin Pathol. 2008 Feb;61(2):203-8 [17827398.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):971-6 [18281528.001]
  • [Cites] Neuropathol Appl Neurobiol. 2008 Oct;34(5):547-54 [18053027.001]
  • [Cites] Cancer Sci. 2006 Mar;97(3):226-34 [16542220.001]
  • [Cites] Nat Genet. 1999 Nov;23(3):266-8 [10545939.001]
  • [Cites] Hum Pathol. 1999 Nov;30(11):1284-90 [10571506.001]
  • [Cites] Trends Cell Biol. 1999 Dec;9(12):M57-60 [10611684.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):433-7 [10666372.001]
  • [Cites] Oncogene. 2000 Mar 16;19(12):1564-71 [10734316.001]
  • [Cites] Neurosurgery. 2000 Sep;47(3):623-31; discussion 631-2 [10981749.001]
  • [Cites] Virchows Arch. 2001 Jan;438(1):39-48 [11213834.001]
  • [Cites] J Cell Physiol. 2001 May;187(2):137-44 [11267993.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2124-8 [11280776.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3139-44 [11306499.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2107-16 [11733361.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):138-43 [11801550.001]
  • [Cites] Clin Neuropathol. 2003 Jul-Aug;22(4):180-6 [12908754.001]
  • (PMID = 19179424.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2765336
  •  go-up   go-down


76. Kabashi S, Muçaj S, Ahmetgjekaj I, Gashi S, Fazliu I, Dreshaj S, Shala N: Radiological imaging detection of tumors localized in fossa cranii posterior. Med Arh; 2008;62(5-6):271-4
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical application of Magnetic Resonance Imaging (MRI) and Computerized Tomography has provided an earlier detection and treatment of many CNS pathologies.
  • Fifty-nine of them were found to have tumor localized in fossa crani posterior (FCP) without any significant difference between genders (50.8% female vs. 49.2% male, chi2 test=0.02 p=0.896).
  • Tumor types that more often were found in young's individuals were: Astrocytomas with a peak incidence in teenagers (average age was 12-year-old SD +/- 7.5, rank 3-23), next was Medulloblastomas (average age was 11-years-old, SD +/- 2.9, rank 6-16 years) and ependymomas (average age was 6.8-years-old, SD +/- 4.6, rank 1-12).
  • The most frequent tumors in children were medulloblastomas, brainstem gliomas, astrocytomas and ependymomas whereas meningiomas and metastasis were most often found in adults.
  • For FCP tumors detection, MRI had 100% sensitivity, specificity and predictive positive value, whereas brain CT was characterized by 95% sensitivity, 90.4 % specificity and 91% predictive positive value.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469268.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  •  go-up   go-down


77. Phi JH, Park SH, Kim SK, Paek SH, Kim JH, Lee YJ, Cho BK, Park CK, Lee DH, Wang KC: Sox2 expression in brain tumors: a reflection of the neuroglial differentiation pathway. Am J Surg Pathol; 2008 Jan;32(1):103-12
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sox2 expression in brain tumors: a reflection of the neuroglial differentiation pathway.
  • Moreover, it was recently found that brain tumors contain stem cells that resemble normal neuroglial stem cells in many respects.
  • This study was undertaken to describe Sox2 expression in various brain tumors, and to determine whether Sox2 expression is a universal feature of brain tumors, or whether its expression is limited to a specific lineage of brain tumors.
  • Sox2 immunohistochemistry was performed on 194 brain tumor tissues of various kinds.
  • Fetal and adult normal brain tissues obtained by autopsy and brain tissues of epilepsy patients with cortical dysplasia were used as controls.
  • In brain tumors of embryonal origin, supratentorial primitive neuroectodermal tumors showed robust Sox2 expression, whereas medulloblastomas and pineoblastomas did not.
  • The majority of Sox2-positive tumor cells coexpressed glial fibrillary acidic protein, and most Sox2-negative cells in medulloblastomas and pineoblastomas showed neuronal differentiation.
  • This study suggest that Sox2 may be a tumor marker of glial lineages rather than a universal brain tumor stem cell marker, because its expression pattern was found to correspond to differentiation pathways.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. HMGB Proteins / biosynthesis. Neuroglia / cytology. Neuroglia / metabolism. Transcription Factors / biosynthesis
  • [MeSH-minor] Brain / cytology. Brain / embryology. Brain / metabolism. Cell Differentiation. Cell Lineage. Fluorescent Antibody Technique. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. SOXB1 Transcription Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162777.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / HMGB Proteins; 0 / RNA, Messenger; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Transcription Factors
  •  go-up   go-down


78. Lindsey JC, Lusher ME, Anderton JA, Gilbertson RJ, Ellison DW, Clifford SC: Epigenetic deregulation of multiple S100 gene family members by differential hypomethylation and hypermethylation events in medulloblastoma. Br J Cancer; 2007 Jul 16;97(2):267-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic deregulation of multiple S100 gene family members by differential hypomethylation and hypermethylation events in medulloblastoma.
  • Using a pharmacological expression reactivation approach, we screened 16 S100 genes for evidence of epigenetic regulation in medulloblastoma, the most common malignant brain tumour of childhood.
  • Four family members (S100A2, S100A4, S100A6 and S100A10) demonstrated evidence of upregulated expression in multiple medulloblastoma cell lines, following treatment with the DNA methyltransferase inhibitor, 5'-aza-2'-deoxycytidine.
  • Assessment of these genes in the non-neoplastic cerebellum (from which medulloblastomas develop) revealed strong somatic methylation affecting S100A2 and S100A4, whereas S100A6 and S100A10 were unmethylated.
  • Assessed against these normal tissue-specific methylation states, S100A6 and S100A10 demonstrated tumour-specific hypermethylation in medulloblastoma primary tumours (5 out of 40 and 4 out of 35, respectively, both 12%) and cell lines (both 7 out of 9, 78%), which was associated with their transcriptional silencing.
  • In summary, these data characterise complex patterns of somatic methylation affecting S100 genes in the normal cerebellum and demonstrate their disruption causing epigenetic deregulation of multiple S100 family members in medulloblastoma development.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Epigenesis, Genetic. Gene Expression Regulation, Neoplastic. Medulloblastoma / genetics. S100 Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Cell Line, Tumor. Cerebellum / metabolism. Child. Child, Preschool. DNA Methylation. DNA Modification Methylases / antagonists & inhibitors. Female. Humans. Infant. Male

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurobiol Exp (Wars). 2000;60(4):569-75 [11200185.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):45-50 [11786397.001]
  • [Cites] Front Biosci. 2002 May 1;7:d1356-68 [11991838.001]
  • [Cites] Expert Opin Investig Drugs. 2002 Jun;11(6):747-54 [12036419.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5400-13 [12154403.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5906-11 [12384556.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):140-8 [12517790.001]
  • [Cites] FASEB J. 2003 Feb;17(2):235-46 [12554702.001]
  • [Cites] Microsc Res Tech. 2003 Apr 15;60(6):540-51 [12645002.001]
  • [Cites] Gene. 2003 May 22;310:133-42 [12801640.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Jun;62(6):627-32 [12834107.001]
  • [Cites] J Biol Chem. 2004 Jan 16;279(3):2053-62 [14570893.001]
  • [Cites] Oncogene. 2004 Feb 26;23(8):1531-8 [14716296.001]
  • [Cites] Carcinogenesis. 2004 May;25(5):661-8 [14688019.001]
  • [Cites] Biochem Cell Biol. 2004 Aug;82(4):508-15 [15284904.001]
  • [Cites] Biochem J. 2006 Jun 1;396(2):201-14 [16683912.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):739-44 [15280928.001]
  • [Cites] FEBS Lett. 2004 Aug 13;572(1-3):184-8 [15304345.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1111-22 [15336958.001]
  • [Cites] Biochem Soc Trans. 2004 Dec;32(Pt 6):913-5 [15506922.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(16):6117-21 [2385586.001]
  • [Cites] Cancer Res. 1992 Jan 1;52(1):108-16 [1727369.001]
  • [Cites] Neuroreport. 1993 Apr;4(4):383-6 [8499593.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]
  • [Cites] Cell Calcium. 1997 Oct;22(4):243-54 [9481475.001]
  • [Cites] Clin Exp Metastasis. 1998 Jul;16(5):471-9 [10091942.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):26-33 [15665276.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):1955-8 [15900299.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5356-64 [16061848.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2005 Sep 5;51(2):201-14 [16171556.001]
  • [Cites] Prostate. 2005 Dec 1;65(4):322-30 [16015609.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jan;45(1):47-60 [16149064.001]
  • [Cites] J Pediatr. 2005 Dec;147(6):731-8 [16356421.001]
  • [Cites] Neurosurg Focus. 2005 Nov;19(5):E10 [16398460.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):677-80 [16243835.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1199-207 [16424059.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7999-8004 [11691825.001]
  • (PMID = 17579622.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / S100 Proteins; 776B62CQ27 / decitabine; EC 2.1.1.- / DNA Modification Methylases; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ PMC2360310
  •  go-up   go-down


79. Onilude OE, Lusher ME, Lindsey JC, Pearson AD, Ellison DW, Clifford SC: APC and CTNNB1 mutations are rare in sporadic ependymomas. Cancer Genet Cytogenet; 2006 Jul 15;168(2):158-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ependymoma is the second most common malignant brain tumor of childhood; however, its molecular basis is poorly understood.
  • The formation of multiple ependymomas has been reported as an occasional feature of Turcot syndrome type 2 (TS2), a familial cancer syndrome caused by inherited mutations of the APC tumor suppressor gene, and characterised by the concurrence of a primary CNS tumor (predominantly medulloblastoma) and multiple colorectal adenomas.
  • APC is a critical component of the Wnt/Wingless signaling pathway, which is disrupted in sporadic cancers (e.g., colorectal adenomas, hepatocellular carcinomas, and medulloblastomas) by somatic mutations affecting multiple genes encoding alternative pathway components, including APC and CTNNB1 (encoding beta-catenin).
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Chromatography, High Pressure Liquid. DNA Mutational Analysis. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16843107.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / CTNNB1 protein, human; 0 / beta Catenin
  •  go-up   go-down


80. Figols-Ladrón de Guevara J, Lafuente-Sánchez JV: [The medulloblastoma]. Rev Neurol; 2006 Aug 16-31;43(4):213-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The medulloblastoma].
  • INTRODUCTION AND DEVELOPMENT: Medulloblastoma is a cerebellar small cell tumor, whose ancestor cell has not been yet identified in the human normal embriology: its exact origin is, in fact, still unknown.
  • Nevertheless, one of the most acceptable possibilities facing the origin of the tumor is the remaining rests of cerebellar outer granular sheet.
  • It is a predominantly infantile tumor, less frequent in young adults, and World Health Organization (WHO) classification has assignated grade IV of malignancy.
  • In this publication of the WHO, medulloblastomas have been subclassified into: classic, desmoplastic, medulloblastomas with extensive nodularity and advanced neuronal differentiation and large cell medulloblastomas.
  • [MeSH-major] Brain Neoplasms. Medulloblastoma
  • [MeSH-minor] Adult. Cerebellum / pathology. Chromosomes, Human, Pair 17. Diagnosis, Differential. Humans. Isochromosomes. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883510.001).
  • [ISSN] 0210-0010
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Number-of-references] 17
  •  go-up   go-down


81. Furneaux CE, Marshall ES, Yeoh K, Monteith SJ, Mews PJ, Sansur CA, Oskouian RJ, Sharples KJ, Baguley BC: Cell cycle times of short-term cultures of brain cancers as predictors of survival. Br J Cancer; 2008 Nov 18;99(10):1678-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle times of short-term cultures of brain cancers as predictors of survival.
  • Brain tumour material obtained at surgery from 70 patients with glioblastoma, medulloblastoma, astrocytoma, oligodendroglioma and metastatic melanoma was cultured for 7 days on 96-well plates, coated with agarose to prevent proliferation of fibroblasts.
  • For patients with brain cancers of all types, median survival for the < or =10-day and >10-day groups were 5.1 and 12.5 months, respectively (P=0.0009).
  • Lower grade gliomas had longer median culture cycle times (16 days) than those of medulloblastomas (9.9 days), glioblastomas (9.8 days) or melanomas (6.7 days).
  • We conclude that culture cycle times determined using short-term cultures of surgical material from brain tumours correlate with patient survival.
  • [MeSH-major] Brain Neoplasms / physiopathology. Cell Cycle
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Kinetics. Male. Middle Aged. Prognosis. Survival Analysis. Time Factors. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2000 Jun;26(4):405-17 [10873364.001]
  • [Cites] Immunology. 2006 Oct;119(2):254-64 [17005005.001]
  • [Cites] N Engl J Med. 2002 Nov 14;347(20):1566-75 [12432043.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] J Math Biol. 2003 Oct;47(4):295-312 [14523574.001]
  • [Cites] Eur J Cancer. 2004 Apr;40(6):794-801 [15120035.001]
  • [Cites] Prog Biophys Mol Biol. 2004 Jun-Jul;85(2-3):353-68 [15142752.001]
  • [Cites] Oncol Res. 2004;14(6):297-304 [15206492.001]
  • [Cites] Cancer Treat Rep. 1978 Aug;62(8):1117-33 [356975.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 May;24(5):873-80 [3169092.001]
  • [Cites] Br J Cancer. 1988 Oct;58(4):423-31 [3207597.001]
  • [Cites] Br Med Bull. 1991 Jan;47(1):47-63 [1863848.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):340-5 [1738186.001]
  • [Cites] Eur J Cancer. 1995;31A(2):230-7 [7718330.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(2):140-7 [10398993.001]
  • [Cites] J Math Biol. 2004 Oct;49(4):329-57 [15657794.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):505-11 [11173147.001]
  • (PMID = 18854836.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2584938
  •  go-up   go-down


82. Korshunov A, Benner A, Remke M, Lichter P, von Deimling A, Pfister S: Accumulation of genomic aberrations during clinical progression of medulloblastoma. Acta Neuropathol; 2008 Oct;116(4):383-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accumulation of genomic aberrations during clinical progression of medulloblastoma.
  • Medulloblastomas comprise the most frequent malignant brain tumor in childhood and one of the biggest challenges in pediatric oncology.
  • The current concept suggests that these tumors may undergo stepwise progression as it has been shown for other brain tumors.
  • However, conclusive evidence of molecular progression over time has not been demonstrated yet for medulloblastoma.
  • In the present study, 28 pairs of medulloblastoma at primary diagnosis and at the time of recurrence, either occurring as local tumor regrowth or tumor dissemination, were histopathologically and molecularly analyzed.
  • These results suggest that early recurrence in medulloblastoma mainly occurs in tumors with a highly malignant genotype and phenotype per se, whereas late recurrence is often dependent on tumor evolution toward a more malignant biology.
  • Therefore, biopsy of recurrent tumors should be performed to assess the biologic properties of the relapsed tumor, especially when targeted therapy approaches are considered.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 6 / genetics. Medulloblastoma / genetics. Nuclear Proteins / genetics. Oncogene Proteins / genetics. Proto-Oncogene Proteins c-myc / genetics
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Child. Child, Preschool. Cytogenetic Analysis. Disease Progression. Female. Humans. Male. Neoplasm Recurrence, Local / genetics. Prognosis

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18704466.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MYC protein, human; 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / Proto-Oncogene Proteins c-myc
  •  go-up   go-down


83. Sarrazin JL: [Infra tentorial tumors]. J Radiol; 2006 Jun;87(6 Pt 2):748-63
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Tumeurs de la fosse postérieure.
  • Infra tentorial tumors in adults are half as frequent as supra tentorial tumors.
  • Tumors of the pons and cerebellum are fewer but medulloblastomas and hemangioblastomas are located primarily in the cerebellum: they are typical tumors of this area.
  • [MeSH-minor] Adult. Ependymoma / diagnosis. Hemangioblastoma / diagnosis. Humans. Male. Medulloblastoma / diagnosis. Meningioma / diagnosis. Neurilemmoma / diagnosis. Papilloma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778745.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 21
  •  go-up   go-down


84. Valentin MD, Canalle R, Queiroz Rde P, Tone LG: Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors. Sao Paulo Med J; 2009 Sep;127(5):288-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of polymorphisms and protein expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous system tumors.
  • CONTEXT AND OBJECTIVE: Genetic investigation of central nervous system (CNS) tumors provides valuable information about the genes regulating proliferation, differentiation, angiogenesis, migration and apoptosis in the CNS.
  • The aim of our study was to determine the prevalence of genetic polymorphisms (codon 31 and 3' untranslated region, 3'UTR) and protein expression of the cyclin-dependent kinase inhibitor 1A (CDKN1A) gene in patients with and without CNS tumors.
  • DESIGN AND SETTING: Analytical cross-sectional study with a control group, at the Molecular Biology Laboratory, Pediatric Oncology Department, Hospital das Clínicas de Ribeirão Preto.
  • METHODS: 41 patients with CNS tumors and a control group of 161 subjects without cancer and paires for sex, age and ethnicity were genotyped using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
  • Protein analysis was performed on 36 patients with CNS tumors, using the Western Blotting technique.
  • These frequencies were not statistically different (P > 0.05) from those seen in the patients with CNS tumors (19.4% and 0.0%, codon 31; 15.8% and 2.6%, 3'UTR site).
  • The results for medulloblastomas and astrocytomas were similar: neither of them expressed the protein (57.14% and 61.54%, respectively).
  • CONCLUSION: No significant differences in protein expression patterns or polymorphisms of CDKN1A in relation to the three types of CNS tumors were observed among Brazilian subjects.
  • [MeSH-major] Brain Neoplasms / genetics. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Neoplasm Proteins / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] 3' Untranslated Regions / genetics. Adolescent. Child. Child, Preschool. Codon / genetics. Epidemiologic Methods. Female. Humans. Infant. Male. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169278.001).
  • [ISSN] 1806-9460
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / CDKN1A protein, human; 0 / Codon; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Neoplasm Proteins
  •  go-up   go-down


85. Pang JC, Chang Q, Chung YF, Teo JG, Poon WS, Zhou LF, Kong X, Ng HK: Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumor. Hum Pathol; 2005 Jan;36(1):36-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumor.
  • Supratentorial primitive neuroectodermal tumors (SPNETs) and medulloblastomas (MBs) are histologically similar intracranial tumors found in different anatomic locations of the brain.
  • The aim of this study was to evaluate whether DLC-1, a newly identified tumor-suppressor gene on chromosome 8p22, is involved in the tumorigenesis of MBs and the histologically similar SPNETs.
  • Bisulfite sequencing further verified a densely methylated pattern of 35 CpG sites studied in M1 that were not found in normal brain, indicating that inactivation of DLC-1 by hypermethylation is involved in SPNET.
  • [MeSH-major] Epigenesis, Genetic. Gene Silencing. Neuroectodermal Tumors, Primitive / genetics. Supratentorial Neoplasms / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Base Sequence. Cell Line, Tumor. Cerebellar Neoplasms / genetics. Child. Child, Preschool. Chromosomes, Human, Pair 8 / genetics. CpG Islands. DNA Methylation. Female. GTPase-Activating Proteins. Gene Expression Regulation, Neoplastic. Humans. Infant. Lasers. Loss of Heterozygosity. Male. Medulloblastoma / genetics. Microdissection. Molecular Sequence Data. Promoter Regions, Genetic. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Supratentorial primitive neuroectodermal tumor.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15712180.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DLC1 protein, human; 0 / GTPase-Activating Proteins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


86. Foreid H, Barroso C, Carvalho H, Morgado C, Roque L, Pimentel J: A 22-year-old man with intracraneal hypertension and impaired sensation over the perineum and left foot. Brain Pathol; 2009 Oct;19(4):735-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This young man presented an intracranial hypertension syndrome and brain MRI features of diffuse leptomeningeal enhancement over cerebral and cerebellar hemispheres.
  • A second cerebellar biopsy allowed the diagnosis of a primary diffuse leptomeningeal Primitive Neuroectodermal Tumor (PNET).
  • Besides the paucity of reports of primary leptomeningeal PNET, its differentiation from primary leptomeningeal medulloblastomas is not always clear-cut and is discussed.
  • [MeSH-minor] Apoptosis. Humans. Hydrocephalus / etiology. Hydrocephalus / therapy. Hypesthesia / etiology. Magnetic Resonance Imaging. Male. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19744046.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


87. Brandes AA, Franceschi E, Tosoni A, Reni M, Gatta G, Vecht C, Kortmann RD: Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol Hematol; 2009 Aug;71(2):165-79
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET).
  • Medulloblastoma and supratentorial primitive neuroectodermal tumors are rare diseases in adults.
  • Due to this rarity, few prospective clinical trials have been conducted on medulloblastoma in adults, investigations being based exclusively on retrospective studies; the populations considered in literature are small, and the different treatments given span decades, during which diagnostic procedures, neurosurgical skills and radiotherapy techniques have changed.
  • Unlike pediatric patients, adult medulloblastoma patients have been treated according to risk-adapted therapeutic strategies in only a few series and despite risk-tailored treatments, 20-30% of patients experience recurrence.
  • An important challenge for the future will be the biological characterization of medulloblastoma, with the identification of specific genetic patterns of patients with a better or a worse prognosis.
  • [MeSH-major] Brain Neoplasms. Medulloblastoma. Neuroectodermal Tumors, Primitive
  • [MeSH-minor] Adolescent. Adult. Child. Female. Genetic Predisposition to Disease. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Medulloblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303318.001).
  • [ISSN] 1879-0461
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 71
  •  go-up   go-down


88. Eberhart CG, Chaudhry A, Daniel RW, Khaki L, Shah KV, Gravitt PE: Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus. BMC Cancer; 2005 Feb 17;5:19
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased p53 immunopositivity in anaplastic medulloblastoma and supratentorial PNET is not caused by JC virus.
  • BACKGROUND: p53 mutations are relatively uncommon in medulloblastoma, but abnormalities in this cell cycle pathway have been associated with anaplasia and worse clinical outcomes.
  • We correlated p53 protein expression with pathological subtype and clinical outcome in 75 embryonal brain tumors.
  • METHODS: p53 protein levels were evaluated semi-quantitatively in 64 medulloblastomas, 3 atypical teratoid rhabdoid tumors (ATRT), and 8 supratentorial primitive neuroectodermal tumors (sPNET) using immunohistochemistry.
  • JC viral sequences were analyzed in DNA extracted from 33 frozen medulloblastoma and PNET samples using quantitative polymerase chain reaction.
  • RESULTS: p53 expression was detected in 18% of non-anaplastic medulloblastomas, 45% of anaplastic medulloblastomas, 67% of ATRT, and 88% of sPNET.
  • The increased p53 immunoreactivity in anaplastic medulloblastoma, ATRT, and sPNET was statistically significant.
  • No JC virus was identified in the embryonal brain tumor samples, while an endogenous human retrovirus (ERV-3) was readily detected.
  • CONCLUSION: Immunoreactivity for p53 protein is more common in anaplastic medulloblastomas, ATRT and sPNET than in non-anaplastic tumors, and is associated with worse clinical outcomes.

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Pathol. 2000 Jan;10(1):85-92 [10668898.001]
  • [Cites] J Neurooncol. 1999;45(2):103-10 [10778725.001]
  • [Cites] Genes Dev. 2000 Apr 15;14(8):994-1004 [10783170.001]
  • [Cites] Clin Cancer Res. 2000 Jul;6(7):2759-63 [10914721.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):513-6 [11212243.001]
  • [Cites] J Virol Methods. 2001 Feb;91(2):109-17 [11164492.001]
  • [Cites] Neuropathology. 2001 Jun;21(2):129-37 [11396678.001]
  • [Cites] J Cancer Res Clin Oncol. 2001;127(6):351-8 [11414195.001]
  • [Cites] J Neurooncol. 2001 Mar;52(1):57-62 [11451203.001]
  • [Cites] Nature. 2002 Jan 24;415(6870):436-42 [11807556.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 20;94(4):267-73 [11854388.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):552-60 [11900240.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):115-22 [11916503.001]
  • [Cites] Br J Cancer. 2002 Apr 8;86(7):1117-23 [11953859.001]
  • [Cites] Neuro Oncol. 2002 Jul;4(3):165-70 [12084346.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Aug;28(4):325-33 [12175345.001]
  • [Cites] J Neurooncol. 2002 Aug;59(1):49-61 [12222838.001]
  • [Cites] Cancer Res. 1991 Sep 1;51(17):4721-3 [1873817.001]
  • [Cites] Oncogene. 1992 Jun;7(6):1159-66 [1594246.001]
  • [Cites] Annu Rev Biochem. 1992;61:55-85 [1323237.001]
  • [Cites] Am J Surg Pathol. 1992 Jul;16(7):687-93 [1530108.001]
  • [Cites] Br J Cancer. 1993 Oct;68(4):801-7 [8398711.001]
  • [Cites] Diagn Mol Pathol. 1993 Mar;2(1):23-8 [8287222.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5649-51 [7923211.001]
  • [Cites] Hum Pathol. 1994 Dec;25(12):1341-5 [8001929.001]
  • [Cites] Am J Pathol. 1984 Sep;116(3):455-63 [6089567.001]
  • [Cites] J Natl Cancer Inst. 1987 Sep;79(3):585-91 [3041095.001]
  • [Cites] J Clin Microbiol. 1989 Jun;27(6):1174-9 [2546971.001]
  • [Cites] Acta Neuropathol. 1994;88(5):465-71 [7847076.001]
  • [Cites] Cancer Lett. 1996 Jun 24;104(1):103-13 [8640736.001]
  • [Cites] Cancer Genet Cytogenet. 1998 May;103(1):1-6 [9595036.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2A):849-53 [9615731.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] J Infect Dis. 1998 Dec;178(6):1816-20 [9815242.001]
  • [Cites] Oncogene. 1999 Jan 7;18(1):39-46 [9926918.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):331-9 [10421270.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11519-24 [10500209.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7613-20 [15569993.001]
  • [Cites] Int J Cancer. 2005 Feb 20;113(5):769-74 [15499616.001]
  • [Cites] Childs Nerv Syst. 2002 Oct;18(9-10):485-91 [12382173.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Jun;62(6):627-32 [12834107.001]
  • [Cites] Oncology. 2003;65(1):46-51 [12837982.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5181-91 [12910255.001]
  • [Cites] Brain Res Mol Brain Res. 2004 Feb 5;121(1-2):137-40 [14969745.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3103-11 [15126347.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1157-66 [15451223.001]
  • [Cites] Cancer Res. 1977 Mar;37(3):718-20 [189911.001]
  • [Cites] Prog Clin Biol Res. 1983;105:205-21 [6304758.001]
  • (PMID = 15717928.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / K08 NS043279; United States / NINDS NIH HHS / NS / K08NS43279
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC554768
  •  go-up   go-down


89. Ferretti E, De Smaele E, Po A, Di Marcotullio L, Tosi E, Espinola MS, Di Rocco C, Riccardi R, Giangaspero F, Farcomeni A, Nofroni I, Laneve P, Gioia U, Caffarelli E, Bozzoni I, Screpanti I, Gulino A: MicroRNA profiling in human medulloblastoma. Int J Cancer; 2009 Feb 1;124(3):568-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA profiling in human medulloblastoma.
  • Medulloblastoma is an aggressive brain malignancy with high incidence in childhood.
  • However, no data are yet available on human primary medulloblastomas.
  • A high throughput microRNA expression profiles was performed in human primary medulloblastoma specimens to investigate microRNA involvement in medulloblastoma carcinogenesis.
  • We identified specific microRNA expression patterns which distinguish medulloblastoma differing in histotypes (anaplastic, classic and desmoplastic), in molecular features (ErbB2 or c-Myc overexpressing tumors) and in disease-risk stratification.
  • MicroRNAs expression profile clearly differentiates medulloblastoma from either adult or fetal normal cerebellar tissues.
  • Only a few microRNAs displayed upregulated expression, while most of them were downregulated in tumor samples, suggesting a tumor growth-inhibitory function.
  • This property has been addressed for miR-9 and miR-125a, whose rescued expression promoted medulloblastoma cell growth arrest and apoptosis while targeting the proproliferative truncated TrkC isoform.
  • In conclusion, misregulated microRNA expression profiles characterize human medulloblastomas, and may provide potential targets for novel therapeutic strategies.
  • [MeSH-major] Biomarkers, Tumor / genetics. Cerebellar Neoplasms / genetics. Gene Expression Profiling. Medulloblastoma / genetics. MicroRNAs

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18973228.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] Italy / Telethon / / GGP07118
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs; EC 2.7.10.1 / Receptor, trkC
  •  go-up   go-down


90. Spiller SE, Ravanpay AC, Hahn AW, Olson JM: Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J Neurooncol; 2006 Sep;79(3):259-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma.
  • PURPOSE: Suberoylanilide hydroxamic acid (SAHA) has been studied in adult solid and hematologic malignancies.
  • However, little information has been reported on the effects of SAHA on central nervous system (CNS) tumors including medulloblastoma, the most common malignant brain tumor in children.
  • We investigated SAHA in preclinical medulloblastoma models to determine its anti-cancer efficacy as well as its ability to affect intracranial lesions when administered systemically.
  • EXPERIMENTAL DESIGN AND RESULTS: Tissue culture studies were performed treating primary human fibroblasts, established medulloblastoma cell lines, and primary human medulloblastoma tumors with SAHA.
  • At 10 microM concentration, SAHA had little effect on normal fibroblasts but caused >90% apoptosis in cultured medulloblastoma cells.
  • Primary medulloblastomas from patients were sensitive to SAHA compared to vehicle alone in ex vivo studies.
  • In athymic mice with medulloblastoma xenograft tumors, oral SAHA resulted in apoptosis of tumor tissue and significantly slowed tumor growth.
  • In the ND2:Smo transgenic mouse medulloblastoma model, SAHA treatment caused significant apoptosis in these cerebellar tumors.
  • CONCLUSIONS: SAHA effectively induces cell death in established medulloblastoma cell lines, human patient primary tumor cultures, medulloblastoma xenografts and intracranial spontaneous medulloblastomas.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cerebellar Neoplasms / drug therapy. Hydroxamic Acids / pharmacology. Medulloblastoma / drug therapy

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Vorinostat .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16645722.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA112350-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hydroxamic Acids; 58IFB293JI / vorinostat
  •  go-up   go-down


91. Brugières L, Pierron G, Chompret A, Paillerets BB, Di Rocco F, Varlet P, Pierre-Kahn A, Caron O, Grill J, Delattre O: Incomplete penetrance of the predisposition to medulloblastoma associated with germ-line SUFU mutations. J Med Genet; 2010 Feb;47(2):142-4
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete penetrance of the predisposition to medulloblastoma associated with germ-line SUFU mutations.
  • METHODS AND RESULTS: Germline SUFU mutations were identified in two families with several children under 3 years of age diagnosed with medulloblastoma.
  • All medulloblastomas in which the histology was reviewed were of the desmoplastic subtype, including three with the rare extensive nodularity subtype.
  • Among the 25 mutation carriers identified in the two families, seven developed medulloblastomas.
  • These are mainly medulloblastomas with extensive nodularity or typical desmoplastic/nodular medulloblastomas.
  • [MeSH-major] Cerebellar Neoplasms / genetics. Germ-Line Mutation. Medulloblastoma / genetics. Penetrance. Repressor Proteins / genetics
  • [MeSH-minor] Adult. Child, Preschool. DNA Mutational Analysis. Family. Female. Genetic Predisposition to Disease. Humans. Infant. Male. Pedigree

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19833601.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Repressor Proteins; 0 / SUFU protein, human
  •  go-up   go-down


92. Campbell RM, Mader RD, Dufresne RG Jr: Meningiomas after medulloblastoma irradiation treatment in a patient with basal cell nevus syndrome. J Am Acad Dermatol; 2005 Nov;53(5 Suppl 1):S256-9
Genetic Alliance. consumer health - Nevus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningiomas after medulloblastoma irradiation treatment in a patient with basal cell nevus syndrome.
  • A 23-year-old woman with basal cell nevus syndrome (BCNS), or Gorlin's syndrome, was given the diagnosis at age 2 years of a medulloblastoma that was resected and treated postoperatively with craniospinal irradiation.
  • This case reviews early presentation of BCNS, newly described differences between medulloblastomas in patients with BCNS and nonsyndromic medulloblastomas, and global assessment of patients by the treating dermatologist of this patient population.
  • [MeSH-major] Basal Cell Nevus Syndrome / epidemiology. Cerebellar Neoplasms / radiotherapy. Medulloblastoma / radiotherapy. Meningeal Neoplasms / epidemiology. Meningioma / epidemiology
  • [MeSH-minor] Adult. Brain Neoplasms / epidemiology. Female. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Parietal Lobe. Radiotherapy Dosage. Time Factors

  • Genetic Alliance. consumer health - Medulloblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227103.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


93. Warnke PC, Timmer J, Ostertag CB, Kopitzki K: Capillary physiology and drug delivery in central nervous system lymphomas. Ann Neurol; 2005 Jan;57(1):136-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Capillary physiology and drug delivery in central nervous system lymphomas.
  • To evaluate whether the chemosensitivity of primary central nervous system lymphomas to water-soluble drugs could result from improved drug delivery, we quantitatively assessed pharmacokinetic factors in seven patients.
  • The capillary permeability surface product was found to be significantly increased in central nervous system lymphomas compared with glioblastoma multiforme, medulloblastomas, and metastases.
  • Our results suggest favorable pharmacokinetics to water- and lipid-soluble drugs in primary central nervous system lymphomas.
  • [MeSH-major] Capillaries / physiopathology. Central Nervous System Neoplasms / physiopathology. Lymphoma / physiopathology. Regional Blood Flow / physiology
  • [MeSH-minor] Adult. Aged. Brain Mapping. Contrast Media / administration & dosage. Drug Delivery Systems. Female. Humans. Image Processing, Computer-Assisted / methods. Iopamidol / administration & dosage. Male. Middle Aged. Models, Theoretical. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15622544.001).
  • [ISSN] 0364-5134
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; JR13W81H44 / Iopamidol
  •  go-up   go-down


94. Fukuda T, Akiyama N, Ikegami M, Takahashi H, Sasaki A, Oka H, Komori T, Tanaka Y, Nakazato Y, Akimoto J, Tanaka M, Okada Y, Saito S: Expression of hydroxyindole-O-methyltransferase enzyme in the human central nervous system and in pineal parenchymal cell tumors. J Neuropathol Exp Neurol; 2010 May;69(5):498-510
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hydroxyindole-O-methyltransferase enzyme in the human central nervous system and in pineal parenchymal cell tumors.
  • Pineal parenchymal tumor (PPT) cells usually show immunoreactivity for synaptophysin, neuron-specific enolase, neurofilament protein, class III beta-tubulin, tau protein, PGP9.5, chromogranin, serotonin, retinal S-antigen, and rhodopsin, but these markers are not specific for PPTs.
  • We hypothesized that HIOMT could serve as a tumor marker of PPTs, and we investigated HIOMT localization and HIOMT expression in samples of normal human tissue and in PPTs, primitive neuroectodermal tumors, and medulloblastomas.
  • The proportions of HIOMT-immunoreactive cells successively decreased in the following tumors: pineocytoma, pineal parenchymal tumor of intermediate differentiation, and pineoblastoma.
  • A few HIOMT-immunoreactive cells were observed in one of 6 primitive neuroectodermal tumors and 23 of 42 medulloblastomas.
  • [MeSH-major] Acetylserotonin O-Methyltransferase / metabolism. Brain Neoplasms / pathology. Central Nervous System / enzymology. Pineal Gland / pathology. Pinealoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Animals. Arrestin / metabolism. Cell Line, Tumor. Child. Child, Preschool. Eye Proteins / genetics. Eye Proteins / metabolism. Female. Green Fluorescent Proteins / genetics. Humans. Infant. Male. Middle Aged. Nerve Tissue Proteins / metabolism. Neurons / metabolism. Plant Lectins / metabolism. RNA, Messenger / metabolism. Retina / pathology. Transfection / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20418777.001).
  • [ISSN] 1554-6578
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arrestin; 0 / Eye Proteins; 0 / Nerve Tissue Proteins; 0 / Plant Lectins; 0 / RNA, Messenger; 0 / Ricinus communis agglutinin-1; 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins; EC 2.1.1.4 / Acetylserotonin O-Methyltransferase
  •  go-up   go-down


95. Han SR, Sohn MJ, Yoon SW, Yee GT, Choi CY, Lee DJ, Whang CJ: Extracranial metastases of a supratentorial primitive neuroectodermal tumour. J Clin Neurosci; 2007 Jan;14(1):55-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracranial metastases from primary central nervous system (CNS) tumours have rarely been reported in the literature, and glioblastomas and medulloblastomas constitute the majority of these.
  • The tendency of supratentorial primitive neuroectodermal tumours (PNET) to spread within the CNS is well-known, but few cases of extracranial metastases of supratentorial PNET have been reported.
  • [MeSH-minor] Adult. Fatal Outcome. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17092726.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


96. Li KK, Pang JC, Ching AK, Wong CK, Kong X, Wang Y, Zhou L, Chen Z, Ng HK: miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1. Hum Pathol; 2009 Sep;40(9):1234-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1.
  • Given that miR-124 is preferentially expressed in differentiating and mature neurons and external granule cells of cerebellum are thought to be cells-of-origins of medulloblastomas, we investigated if miR-124 played a role in the development of medulloblastomas.
  • Quantitative expression analysis of 29 medulloblastomas demonstrated significant down-regulation of miR-124 in 21 (72%) tumors by at least 2-fold, with 11 of them exhibiting greater than 10-fold reduced level compared to normal cerebella (P < .01).
  • Ectopic expression of miR-124 in medulloblastoma cell lines, ONS-76 and DAOY, inhibited cell proliferation.
  • Knockdown of SLC16A1 by siRNA induced cell death in medulloblastoma cells.
  • In conclusion, our study demonstrates that miR-124 deregulation is common in medulloblastomas, and restoration of its function inhibits cell proliferation, suggesting that miR-124 may act as a growth suppressor.
  • Our findings also raise the possibility that the miR-124/SLC16A1 pathway may represent a novel therapeutic target for treatment of malignant medulloblastomas.
  • [MeSH-major] Down-Regulation / genetics. Medulloblastoma / genetics. MicroRNAs / genetics. MicroRNAs / physiology. Monocarboxylic Acid Transporters / genetics. Symporters / genetics
  • [MeSH-minor] Adolescent. Adult. Cell Line, Tumor. Cell Proliferation. Child. Child, Preschool. Cohort Studies. Female. Gene Expression Regulation, Neoplastic. Genes, Reporter. Humans. Luciferases, Renilla / metabolism. Male. RNA, Small Interfering / metabolism. Transfection

  • Genetic Alliance. consumer health - Medulloblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19427019.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MIRN124 microRNA, human; 0 / MicroRNAs; 0 / Monocarboxylic Acid Transporters; 0 / RNA, Small Interfering; 0 / Symporters; 0 / monocarboxylate transport protein 1; EC 1.13.12.5 / Luciferases, Renilla
  •  go-up   go-down


97. Dave KA, Bordey A: GABA increases Ca2+ in cerebellar granule cell precursors via depolarization: implications for proliferation. IUBMB Life; 2009 May;61(5):496-503
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The amino acids glutamate and gamma-aminobutyric acid (GABA) have primarily been characterized as the most prevalent excitatory and inhibitory, respectively, neurotransmitters in the vertebrate central nervous system.
  • GABA, glutamate, and their complement of receptors are essential signaling molecules that regulate developmental processes in both embryonic and young adult mammals.
  • From our review of the literature and these data, we hypothesize that GABA(A) receptors and metabotropic glutamate receptors may be a novel target for the pharmacological regulation of the cerebellar tumors, medulloblastomas.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Neurosci. 1995 Dec;18(12):515-9 [8638289.001]
  • [Cites] Brain Res Mol Brain Res. 1996 Apr;37(1-2):239-48 [8738157.001]
  • [Cites] J Neurooncol. 1996 Jul;29(1):35-43 [8817414.001]
  • [Cites] J Neurosci. 1996 Oct 15;16(20):6414-23 [8815920.001]
  • [Cites] J Neurosci Res. 1996 Oct 15;46(2):164-78 [8915893.001]
  • [Cites] Neurochem Int. 1996 Oct;29(4):335-56 [8939442.001]
  • [Cites] J Chem Neuroanat. 1997 Jul;13(2):77-93 [9285353.001]
  • [Cites] J Neurophysiol. 1998 Jan;79(1):439-46 [9425212.001]
  • [Cites] Neuroreport. 1998 Jul 13;9(10):2319-23 [9694221.001]
  • [Cites] Eur J Neurosci. 1998 Jun;10(6):2173-84 [9753103.001]
  • [Cites] Perspect Dev Neurobiol. 1998;5(2-3):305-22 [9777645.001]
  • [Cites] Nature. 1999 Jan 21;397(6716):251-5 [9930699.001]
  • [Cites] J Physiol. 1999 May 15;517 ( Pt 1):51-8 [10226148.001]
  • [Cites] Neurochem Int. 1999 May;34(5):379-85 [10397365.001]
  • [Cites] J Comp Neurol. 1999 Jul 26;410(2):243-55 [10414530.001]
  • [Cites] J Biol Chem. 1950 Nov;187(1):35-9 [14794686.001]
  • [Cites] J Biol Chem. 1950 Nov;187(1):55-63 [14794689.001]
  • [Cites] J Neurochem. 1957;1(4):334-9 [13476199.001]
  • [Cites] J Neurochem. 1960 Sep;6:117-41 [13718948.001]
  • [Cites] J Physiol. 1963 Feb;165:274-304 [14035891.001]
  • [Cites] Nature. 1964 Mar 28;201:1294-6 [14151407.001]
  • [Cites] J Physiol. 1955 Nov 28;130(2):446-55 [13278911.001]
  • [Cites] J Neurosci. 2004 Nov 17;24(46):10343-52 [15548648.001]
  • [Cites] Neuroscience. 2005;130(3):567-80 [15590141.001]
  • [Cites] Dev Neurosci. 2004 Mar-Aug;26(2-4):218-28 [15711062.001]
  • [Cites] Nat Neurosci. 2005 Jun;8(6):723-9 [15908947.001]
  • [Cites] Cell Death Differ. 2005 Aug;12(8):1124-33 [15947794.001]
  • [Cites] Nat Neurosci. 2005 Sep;8(9):1179-87 [16116450.001]
  • [Cites] Hippocampus. 2006;16(3):267-70 [16425227.001]
  • [Cites] Cell Cycle. 2006 Apr;5(7):722-8 [16582623.001]
  • [Cites] Curr Top Med Chem. 2006;6(10):949-60 [16787269.001]
  • [Cites] Histol Histopathol. 2006 Oct;21(10):1135-41 [16835836.001]
  • [Cites] Brain Res. 1973 Nov 9;62(1):1-35 [4203033.001]
  • [Cites] Science. 1974 Sep 20;185(4156):1012-21 [4152810.001]
  • [Cites] Nature. 1981 Mar 12;290(5802):149-52 [6259535.001]
  • [Cites] Nature. 1984 Feb 2-8;307(5950):462-5 [6320006.001]
  • [Cites] Nature. 1987 Feb 5-11;325(6104):522-5 [2433593.001]
  • [Cites] Cancer Metastasis Rev. 1987;5(4):343-65 [2882864.001]
  • [Cites] J Physiol. 1987 Apr;385:243-86 [2443667.001]
  • [Cites] J Neurosci. 2006 Aug 9;26(32):8388-97 [16899734.001]
  • [Cites] Neuroscience. 2006 Dec13;143(3):757-67 [17008020.001]
  • [Cites] Brain Res Rev. 2007 Jan;53(1):124-34 [16949673.001]
  • [Cites] Trends Neurosci. 2007 Jan;30(1):1-8 [17116335.001]
  • [Cites] Physiol Rev. 2007 Oct;87(4):1215-84 [17928584.001]
  • [Cites] Cancer Invest. 2007 Oct;25(7):574-83 [18027151.001]
  • [Cites] J Neurochem. 2008 Jan;104(1):155-72 [17944877.001]
  • [Cites] J Neurosci. 2001 Jan 15;21(2):527-40 [11160432.001]
  • [Cites] Prog Neurobiol. 2001 Sep;65(1):1-105 [11369436.001]
  • [Cites] Cell Tissue Res. 2001 Aug;305(2):187-202 [11545256.001]
  • [Cites] Neuroscience. 2002;110(3):403-20 [11906782.001]
  • [Cites] J Physiol. 2002 Jun 15;541(Pt 3):753-67 [12068038.001]
  • [Cites] Nat Rev Neurosci. 2002 Sep;3(9):715-27 [12209120.001]
  • [Cites] Neuroscientist. 2002 Dec;8(6):551-61 [12467377.001]
  • [Cites] J Neurosci. 2003 Mar 15;23(6):2239-50 [12657683.001]
  • [Cites] J Neurosci. 2003 Apr 15;23(8):3278-94 [12716935.001]
  • [Cites] Cerebellum. 2002 Jan-Mar;1(1):19-26 [12879970.001]
  • [Cites] J Physiol. 2003 Aug 1;550(Pt 3):785-800 [12807990.001]
  • [Cites] J Neurophysiol. 2003 Oct;90(4):2291-302 [12801891.001]
  • [Cites] J Neurosci Res. 2003 Dec 1;74(5):676-87 [14635219.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8090-6 [14678958.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Mar 5;315(2):493-6 [14766235.001]
  • [Cites] J Neurosci. 2004 Sep 1;24(35):7623-31 [15342728.001]
  • [Cites] Nature. 1966 Sep 24;211(5056):1372-4 [5969831.001]
  • [Cites] Biochim Biophys Acta. 1972 Aug 9;274(2):313-22 [5049000.001]
  • [Cites] Nature. 2008 Jan 24;451(7177):460-4 [18185516.001]
  • [Cites] Life Sci. 2008 Feb 27;82(9-10):536-41 [18222491.001]
  • [Cites] J Physiol. 2008 Aug 15;586(16):3739-43 [18467361.001]
  • [Cites] Carcinogenesis. 2008 Oct;29(10):1979-85 [18310090.001]
  • [Cites] Neurosci Lett. 2000 Jun 16;287(1):53-6 [10841989.001]
  • [Cites] J Neurophysiol. 2000 Oct;84(4):1697-707 [11024062.001]
  • [Cites] J Cereb Blood Flow Metab. 2000 Dec;20(12):1669-80 [11129783.001]
  • [Cites] J Physiol. 1988 May;399:207-26 [2457087.001]
  • [Cites] Brain Res. 1988 Sep;464(2):97-105 [2464409.001]
  • [Cites] Trends Neurosci. 1988 Mar;11(3):112-6 [2465608.001]
  • [Cites] Prog Neurobiol. 1989;32(6):471-533 [2664881.001]
  • [Cites] J Physiol. 1989 Aug;415:555-82 [2484210.001]
  • [Cites] J Neurophysiol. 1991 Feb;65(2):247-63 [1673153.001]
  • [Cites] Neuroscience. 1991;43(1):111-9 [1922763.001]
  • [Cites] Trends Pharmacol Sci. 2000 Jan;21(1):16-9 [10637650.001]
  • [Cites] J Comp Neurol. 2000 Feb 28;418(1):106-20 [10701759.001]
  • [Cites] J Neurosci. 2000 Mar 15;20(6):2073-85 [10704481.001]
  • [Cites] Can J Physiol Pharmacol. 1991 Jul;69(7):1049-56 [1954562.001]
  • [Cites] Physiol Rev. 1992 Jan;72(1):101-63 [1731369.001]
  • [Cites] J Neurosci. 1992 Mar;12(3):1063-76 [1312132.001]
  • [Cites] Development. 1991 Nov;113(3):755-65 [1821847.001]
  • [Cites] J Comp Neurol. 1992 Aug 1;322(1):121-35 [1430307.001]
  • [Cites] Development. 1993 Jan;117(1):97-104 [8223263.001]
  • [Cites] J Neuropathol Exp Neurol. 1994 Jan;53(1):61-71 [8301321.001]
  • [Cites] Neuropharmacology. 1993 Nov;32(11):1239-48 [7509049.001]
  • [Cites] Annu Rev Neurosci. 1994;17:31-108 [8210177.001]
  • [Cites] J Neurosci. 1995 Jun;15(6):4687-92 [7790933.001]
  • [Cites] J Neurosci Methods. 1995 Mar;57(1):27-35 [7540702.001]
  • [Cites] Annu Rev Neurosci. 1995;18:385-408 [7605067.001]
  • [Cites] Science. 1995 Aug 18;269(5226):977-81 [7638623.001]
  • [Cites] J Comp Neurol. 1995 Oct 2;360(4):555-70 [8801249.001]
  • [Cites] Neuron. 1995 Dec;15(6):1287-98 [8845153.001]
  • (PMID = 19391160.001).
  • [ISSN] 1521-6551
  • [Journal-full-title] IUBMB life
  • [ISO-abbreviation] IUBMB Life
  • [Language] ENG
  • [Grant] United States / NIDCD NIH HHS / DC / R01 DC007681; United States / NINDS NIH HHS / NS / NS048256; United States / NIDCD NIH HHS / DC / DC007681-02; United States / NIDCD NIH HHS / DC / DC007681; United States / NINDS NIH HHS / NS / NS048256-04; United States / NINDS NIH HHS / NS / R01 NS048256; United States / NINDS NIH HHS / NS / R01 NS048256-04; United States / NIDCD NIH HHS / DC / R01 DC007681-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, GABA-A; 3KX376GY7L / Glutamic Acid; 56-12-2 / gamma-Aminobutyric Acid; SY7Q814VUP / Calcium
  • [Number-of-references] 104
  • [Other-IDs] NLM/ NIHMS100672; NLM/ PMC2675662
  •  go-up   go-down


98. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol; 2008 Dec;116(6):597-602
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the IDH1 codon 132 mutation in brain tumors.
  • We analyzed the genomic region spanning wild type R132 of IDH1 by direct sequencing in 685 brain tumors including 41 pilocytic astrocytomas, 12 subependymal giant cell astrocytomas, 7 pleomorphic xanthoastrocytomas, 93 diffuse astrocytomas, 120 adult glioblastomas, 14 pediatric glioblastomas, 105 oligodendrogliomas, 83 oligoastrocytomas, 31 ependymomas, 58 medulloblastomas, 9 supratentorial primitive neuroectodermal tumors, 17 schwannomas, 72 meningiomas and 23 pituitary adenomas.
  • The very high frequency of IDH1 mutations in WHO grade II astrocytic and oligodendroglial gliomas suggests a role in early tumor development.
  • [MeSH-major] Brain Neoplasms / genetics. Isocitrate Dehydrogenase / genetics. Mutation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18985363.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase
  •  go-up   go-down


99. Sasajima T, Kinouchi H, Naitoh Y, Tomura N, Watarai J, Mizoi K: 123I-metaiodobenzylguanidine single-photon emission computerized tomography in brain tumors - a preliminary study. J Neurooncol; 2006 Apr;77(2):185-91
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 123I-metaiodobenzylguanidine single-photon emission computerized tomography in brain tumors - a preliminary study.
  • The present study aimed to explore a potential of (123)I-MIBG to differentiate embryonal tumors from other types of brain tumors.
  • METHODS: Sixteen patients with brain tumors including three medulloblastomas, one neuroblastoma, six gliomas, and six meningiomas were examined with single-photon emission computerized tomography (SPECT) using (123)I-MIBG.
  • The (123)I-MIBG uptake of tumors was defined as the ratios of tumor/nontumor (early and delayed T/NT) on SPECT images scanned 30 min and 6 h after intravenous injection of the tracer, respectively.
  • RESULTS: The T/NT ratios on the early images for embryonal tumors (medulloblastomas and neuroblastoma), gliomas, and meningiomas were 3.2+/-1.7 (mean+/-SD), 1.4+/-0.3, and 1.6+/-0.5, respectively.
  • CONCLUSION: Early high accumulation and high retention on delayed imaging may indicate a possibility of (123)I-MIBG SPECT in differentiating embryonal brain tumors from gliomas and meningiomas.
  • [MeSH-major] 3-Iodobenzylguanidine. Brain Neoplasms / radionuclide imaging. Glioma / radionuclide imaging. Meningioma / radionuclide imaging. Neoplasms, Germ Cell and Embryonal / radionuclide imaging. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged, 80 and over. Animals. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Middle Aged. Sensitivity and Specificity. Tomography, Emission-Computed, Single-Photon

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16314956.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down


100. Yan B, Omar FM, Das K, Ng WH, Lim C, Shiuan K, Yap CT, Salto-Tellez M: Characterization of Numb expression in astrocytomas. Neuropathology; 2008 Oct;28(5):479-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Numb has also been reported to function as a tumor suppressor in breast cancers and medulloblastomas.
  • Given its role in maintaining neural progenitor pools in animal models and its reported role as a tumor suppressor, Numb could potentially contribute to astrocytoma oncogenesis.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Membrane Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Child. Child, Preschool. Female. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Neuroglia / metabolism. Neurons / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384513.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 0 / Numb protein, human
  •  go-up   go-down






Advertisement